Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________________________

FORM 10-Q

_____________________________________________


x			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
			For the quarterly period ended March 31, 2024


o			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
			For the transition period from to

Commission file number 001-39535

SHARECARE, INC.

(Exact name of registrant as specified in its charter)


Delaware						85-1365053
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

255 East Paces Ferry Road NE, Suite 700 Atlanta, Georgia						30305
(Address of Principal Executive Offices)						(Zip Code)

(404) 671-4000

(Registrant's telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	SHCR	The Nasdaq Stock Market LLC
Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $11.50 per share	SHCRW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer	o	Accelerated filer	x
Non-accelerated filer	o	Smaller reporting company	o
		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

As of May 6, 2024, there were 362,409,958 shares of the registrant’s common stock, par value $0.0001 per share, outstanding.

Table of Contents

Sharecare, Inc.

Table of Contents


		Page
Part I. Financial Information
Item 1.	Financial Statements	1
	Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 (unaudited)	1
	Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and 2023 (unaudited)	2
	Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the three months ended March 31, 2024 and 2023 (unaudited)	3
	Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 (unaudited)	5
	Notes to Consolidated Financial Statements (unaudited)	6
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	31
Item 4.	Controls and Procedures	32

Part II. Other Information
Item 1.	Legal Proceedings	34
Item 1A.	Risk Factors	34
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	34
Item 3.	Defaults Upon Senior Securities	34
Item 4.	Mine Safety Disclosures	34
Item 5.	Other Information	34
Item 6.	Exhibits	35
Signatures		36

Table of Contents

Part I - Financial Information

ITEM 1. FINANCIAL STATEMENTS

SHARECARE, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except share and per share amounts)


	As of March 31, 2024		As of December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	100,320	$	128,187
Accounts receivable, net (net of allowance for doubtful accounts of $8,348 and $8,544, respectively)	124,936		128,173
Other receivables	2,213		2,262
Prepaid expenses	9,875		6,007
Other current assets	2,814		3,178
Total current assets	240,158		267,807
Property and equipment, net	2,751		3,375
Other long-term assets	13,599		13,863
Intangible assets, net	130,263		136,552
Goodwill	191,860		192,037
Total assets	$	578,631	$	613,634
Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity
Current liabilities:
Accounts payable	$	45,530	$	45,388
Accrued expenses and other current liabilities (Note 3)	55,516		65,706
Deferred revenue	5,735		5,517

Total current liabilities	106,781		116,611
Warrant liabilities	317		403
Long-term debt	586		519
Other long-term liabilities	7,171		8,032
Total liabilities	114,855		125,565
Commitments and contingencies (Note 7)
Series A redeemable convertible preferred stock, $0.0001 par value; 5,000,000 shares authorized; 5,000,000 shares issued and outstanding, aggregate liquidation preference of $50,000 as of March 31, 2024 and December 31, 2023	58,205		58,205
Stockholders’ equity:
Common stock $0.0001 par value; 600,000,000 and 600,000,000 shares authorized; 358,572,273 and 353,430,357 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	36		35
Additional paid-in capital	1,168,869		1,157,737
Accumulated other comprehensive loss	(2,551)		(2,263)
Accumulated deficit	(760,460)		(725,373)
Total Sharecare, Inc. stockholders’ equity	405,894		430,136
Noncontrolling interest in subsidiaries	(323)		(272)
Total stockholders’ equity	405,571		429,864
Total liabilities, redeemable convertible preferred stock and stockholders’ equity	$	578,631	$	613,634

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

SHARECARE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except share and per share amounts)


	Three Months Ended March 31,
	2024		2023
Revenue	$	90,861	$	116,295
Costs and operating expenses:
Costs of revenue (exclusive of depreciation and amortization)	51,121		67,890
Sales and marketing	13,558		15,348
Product and technology	14,544		20,808
General and administrative	34,907		34,121
Depreciation and amortization	13,331		14,781
Total costs and operating expenses	127,461		152,948
Loss from operations	(36,600)		(36,653)
Other income:
Interest income	1,274		1,680
Interest expense	(217)		(430)
Other income	368		429
Total other income	1,425		1,679
Loss before income tax benefit (expense)	(35,175)		(34,974)
Income tax benefit (expense)	31		(31)
Net loss	(35,144)		(35,005)
Net loss attributable to noncontrolling interest in subsidiaries	(57)		(346)
Net loss attributable to Sharecare, Inc.	$	(35,087)	$	(34,659)

Net loss per share attributable to common stockholders, basic and diluted	$	(0.10)	$	(0.10)
Weighted-average common shares outstanding, basic and diluted	354,208,908		352,923,217

Net loss	$	(35,144)	$	(35,005)
Other comprehensive loss adjustments:
Foreign currency translation	(282)		307
Comprehensive loss	(35,426)		(34,698)
Comprehensive loss (income) attributable to noncontrolling interest in subsidiaries	(51)		(289)
Comprehensive loss attributable to Sharecare, Inc.	$	(35,375)	$	(34,409)

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

SHARECARE, INC.

CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

(In thousands, except share amounts)


	Redeemable Convertible Preferred Stock			Common Stock			Additional Paid-In Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Noncontrolling Interest		Total Stockholders’ Equity (Deficit)
	Shares	Amount		Shares	Amount
Balance at December 31, 2023	5,000,000	$	58,205	353,430,357	$	35	$	1,157,737	$	(2,263)	$	(725,373)	$	(272)	$	429,864
Stock options exercised	—	—		40,278	—		24		—		—		—		24
Common stock issued upon vesting of restricted stock units	—	—		7,674,863	1		(1)		—		—		—		—
Issuance of warrants in connection with debt and revenue arrangements	—	—		—	—		27		—		—		—		27
Share-based compensation	—	—		—	—		13,866		—		—		—		13,866
Net income (loss) attributable to noncontrolling interest in subsidiaries	—	—		—	—		—		—		—		(57)		(57)
Currency translation adjustment	—	—		—	—		—		(288)		—		6		(282)
Common stock repurchased related to tax withholding for exercised employee stock options and vested restricted stock units	—	—		(2,573,225)	—		(2,784)		—		—		—		(2,784)
Net income (loss) attributable to Sharecare, Inc.	—	—		—	—		—		—		(35,087)		—		(35,087)
Balance at March 31, 2024	5,000,000	$	58,205	358,572,273	$	36	$	1,168,869	$	(2,551)	$	(760,460)	$	(323)	$	405,571

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

SHARECARE, INC.

CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

(In thousands, except share amounts)


	Redeemable Convertible Preferred Stock			Common Stock			Additional Paid-In Capital		Accumulated Other Comprehensive Loss		Accumulated Deficit		Noncontrolling Interest		Total Stockholders’ Equity (Deficit)
	Shares	Amount		Shares	Amount
Balance at December 31, 2022	5,000,000	$	58,205	354,463,620	$	35	$	1,120,024	$	(2,794)	$	(595,820)	$	1,155	$	522,600
Stock options exercised	—	—		281,042	—		282		—		—		—		282
Common stock issued upon vesting of restricted stock units	—	—		1,759,615	—		—		—		—		—		—
Issuance of warrants in connection with debt and revenue arrangements	—	—		—	—		14		—		—		—		14
Cumulative effect of adopting ASU 2016-13	—	—		—	—		—		—		(1,055)		—		(1,055)
Share-based compensation	—	—		—	—		10,406		—		—		—		10,406
Net income (loss) attributable to noncontrolling interest in subsidiaries	—	—		—	—		—		—		—		(346)		(346)
Currency translation adjustment	—	—		—	—		—		250		—		57		307
Common stock repurchased related to tax withholding for exercised employee stock options and vested restricted stock units	—	—		(214,984)	—		(396)		—		—		—		(396)
Net income (loss) attributable to Sharecare, Inc.	—	—		—	—		—		—		(34,659)		—		(34,659)
Other	—	—		—	—		(131)		—		—		—		(131)
Balance at March 31, 2023	5,000,000	$	58,205	356,289,293	$	35	$	1,130,199	$	(2,544)	$	(631,534)	$	866	$	497,022

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

SHARECARE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands, except share and per share amounts)


	Three Months Ended March 31,
	2024		2023
Cash flows from operating activities:
Net loss	$	(35,144)	$	(35,005)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	13,331		14,781
Non-cash interest expense	68		254
Amortization of contract liabilities	—		(451)
Accretion of contract liabilities	—		68
Lease right-of-use assets expense	566		1,138
Change in fair value of warrant liability and contingent consideration	(379)		(138)
Share-based compensation	13,596		9,969
Deferred income taxes	(36)		59
Other	151		2,120
Changes in operating assets and liabilities:
Accounts receivable, net	2,842		(1,387)
Prepaid expenses and other assets	(3,747)		(5,795)
Accounts payable and accrued expenses	(10,422)		(10,608)
Operating lease liabilities	(635)		794
Deferred revenue	218		703
Net cash used in operating activities	(19,591)		(23,498)
Cash flows from investing activities:
Purchases of property and equipment	(51)		(368)
Capitalized internal-use software costs	(5,135)		(4,806)
Net cash used in investing activities	(5,186)		(5,174)
Cash flows from financing activities:
Payments for shares repurchased	(2,784)		(131)
Proceeds from exercise of common stock options	24		1,023
Payments on financing lease obligations	(285)		(370)
Net cash (used in) provided by financing activities	(3,045)		522
Effect of exchange rates on cash and cash equivalents	(45)		72
Net decrease in cash and cash equivalents	(27,867)		(28,078)
Cash and cash equivalents at beginning of period	128,187		182,508
Cash and cash equivalents at end of period	$	100,320	$	154,430
Supplemental disclosure of cash flow information:
Cash paid for interest	$	151	$	236
Cash paid for amounts included in the measurement of lease liabilities	$	626	$	1,336
Assets obtained in exchange for lease obligations	$	—	$	1,695

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Sharecare, Inc.

Notes to Unaudited Consolidated Financial Statements

(Unaudited)

1.Nature of Business and Significant Accounting Policies

Nature of Business

Sharecare, Inc. (“Sharecare” or the “Company”) was founded in 2009 to develop an interactive health and wellness platform and began operations in October 2010. Sharecare’s virtual health platform is designed to help people, patients, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. The platform is designed to connect each stakeholder to the health management tools they need to drive engagement, establish sustained participation, increase satisfaction, reduce costs, and improve outcomes. Sharecare bridges scientifically validated clinical programs with content to deliver a personalized experience for its members, beginning with the RealAge® test, Sharecare’s health risk assessment that shows members the true age of their body, capitalizing on people’s innate curiosity of how “young” they are to draw them into the platform. The Sharecare platform provides members with a personalized action plan to guide and educate them on the habits and behaviors making the biggest impact, both positive and negative, on their RealAge. Sharecare provides the resources members need to manage their health through lifestyle or disease management and coaching programs, such as diabetes management and smoking cessation, well-being solutions, such as financial health and anxiety management; care navigation tools such as find-a-doctor, prescription savings, clinical decision support, medical records, home care, and more. In January 2023, Sharecare launched Sharecare+, a digital-first, comprehensive advocacy solution designed to deliver value through benefits navigation, clinical engagement, virtual care, and chronic case and utilization management. Additionally, Sharecare provides secure, automated release of information, audit and business consulting services to streamline the medical records process for medical facilities. Sharecare delivers value via its provider, enterprise, and life sciences channels.

Basis of Presentation and Consolidation Policy

The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of Sharecare, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Segment Information

The Company operates as a single operating segment. The Company’s chief operating decision maker is its chief executive officer, who reviews financial information presented on a consolidated basis for purposes of making operating decisions, assessing financial performance and allocating resources for the entire company.

Unaudited Interim Financial Information

The accompanying interim Consolidated Balance Sheet as of March 31, 2024 and the Consolidated Statements of Operations and Comprehensive Loss, Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit), and Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 are unaudited. These unaudited interim consolidated financial statements are presented in accordance with the rules and regulations of the SEC and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with U.S. GAAP. In management’s opinion, the unaudited interim consolidated financial statements have been prepared on the same basis as the annual financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2024 and the Company’s consolidated results of operations and cash flows for the three months ended March 31, 2024 and 2023. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full fiscal year or any other future interim or annual periods. The information contained within the unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s annual financial statements for the year ended December 31, 2023.

Use of Estimates

The preparation of these unaudited interim consolidated financial statements in conformity with GAAP requires the use of management estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the

Table of Contents

Sharecare, Inc.

Notes to Unaudited Consolidated Financial Statements

(Unaudited)

consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include goodwill, revenue recognition, stock-based compensation, and income taxes. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.

Concentration of Credit Risk

The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company’s cash deposits are held with well-known financial institutions and may exceed federally insured limits. The Company grants credit to its customers in the normal course of business and generally requires no collateral from its customers.

Fair Value Measurements

The carrying value of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximates fair value due to their short-term nature.

The Company measures financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires management to maximize the use of observable inputs and minimize the use of unobservable inputs. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between willing market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

•Level 1 — Quoted prices in active markets for identical assets or liabilities

•Level 2 — Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities

•Level 3 — Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability

Assets and Liabilities that are Measured at Fair Value on a Non-recurring Basis

Assets and liabilities that may be measured at fair value on a non-recurring basis relate primarily to the Company’s tangible fixed assets and other intangible assets. For these assets, the Company does not periodically adjust the carrying value to fair value except in the event of an impairment. When the Company determines that an impairment has occurred, the carrying value of the asset is reduced to its fair value and an impairment charge is recorded within operating loss in the Consolidated Statements of Operations and Comprehensive Loss.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable, net, consists of trade accounts receivable which are due under normal trade terms requiring payment, typically within 45 days from the invoice date. The allowance for doubtful accounts is based on management's estimate for expected credit losses for outstanding trade accounts receivable and is recorded as an offset to accounts receivable. Changes in the allowance for doubtful accounts are classified as general and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss. The Company determines expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, customer payment patterns, and adjusts based on expectations of changes in macro-economic conditions and customer-specific information that may impact the collectability of outstanding receivables. The Company reassesses the adequacy of the allowance for doubtful accounts each reporting period.

The changes in the allowance for doubtful accounts are as follows (in thousands):

Table of Contents

Sharecare, Inc.

Notes to Unaudited Consolidated Financial Statements

(Unaudited)


	Three Months Ended March 31,
	2024		2023
Allowance for doubtful accounts – beginning balance	$	8,544	$	7,197
Provision for doubtful accounts	411		1,869
Amounts written off and other adjustments	(607)		(640)
Allowance for doubtful accounts – ending balance	$	8,348	$	8,426

Contract Liabilities

In connection with certain acquisitions, the Company has recognized current and noncurrent contract liabilities, representing off-market values associated with certain wellness program royalty agreements. Amortization of these contract liabilities was $0 and $0.5 million for three months ended March 31, 2024 and 2023, respectively, all of which was included within cost of revenues in the Consolidated Statements of Operations and Comprehensive Loss. Additionally, the Company has recognized certain contract liabilities due to a former related party in the amount of $17.5 million, related to service agreements, which is included in accrued expenses and other current liabilities in the Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023.

Deferred Revenue

The Company records contract liabilities, which consist of deferred revenue and contract billings in excess of earned revenue, pursuant to ASC 606.

Deferred revenues arise from contracts that permit upfront billing and the collection of fees covering the entire contractual service period, which is generally six to twelve months and in advance of the satisfaction of the performance obligations identified within the related contract. As of March 31, 2024 and December 31, 2023, such fees were $5.7 million and $5.5 million, respectively. The Company recognized $1.2 million of revenue during the three months ended March 31, 2024 that was included in deferred revenue at December 31, 2023.

Revenue Recognition

Performance-Based Revenue

Certain contracts place a portion of fees at risk based on achieving certain performance metrics, such as customer cost savings, and/or clinical outcomes improvements (performance-based). The Company uses the most likely amount method to estimate variable consideration for these performance guarantees. The Company includes in the transaction price some, or all, of a variable consideration amount only to the extent that it is not probable that a significant reversal in the amount of cumulative revenue recognized will occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company utilizes customer data to measure performance. Performance-based fees subject to refund that the Company has not recognized as revenues are generally due to either: (1) data from the customer is insufficient or incomplete to measure performance; or (2) interim performance measures indicate that it is not probable that the Company will meet the relevant performance target(s). As of March 31, 2024 and December 31, 2023, such fees included within deferred revenue were $4.8 million and $4.9 million, respectively.

In the event that performance measures are not met by the end of the measurement period, typically one year, some or all of the performance-based fees are required to be refunded. During the settlement process under a contract, which generally occurs six to eight months after the end of a contract year, performance-based fees are reconciled and settled. Approximately $1.5 million and $1.2 million of revenues recognized during the three months ended March 31, 2024 and 2023, respectively, were performance-based. As of March 31, 2024 and 2023, the cumulative amount of performance-based revenues that had met the criteria for recognition and had been recognized but had not yet been settled with customers, totaled $1.9 million and $6.5 million, respectively. During the three months ended March 31, 2024, $0.7 million of revenue was recognized, which related to services provided prior to December 31, 2023.

Remaining Performance Obligations

Remaining performance obligations represent contracted revenues that are non-cancellable and have not yet been recognized due to unsatisfied or partially satisfied performance obligations. This includes deferred revenues and amounts that will be invoiced and recognized as revenues in future periods. As of March 31, 2024, future estimated revenue related to

Table of Contents

Sharecare, Inc.

Notes to Unaudited Consolidated Financial Statements

(Unaudited)

performance obligations with terms of more than one year that are unsatisfied or partially unsatisfied at the end of the reporting period was approximately $61.2 million. As of March 31, 2024, the Company expects to recognize revenue on approximately 91% of these unsatisfied performance obligations over the following 24 months and the remainder thereafter.

Disaggregated Revenue

The following table presents the Company’s revenues disaggregated by revenue source (in thousands):


	Three Months Ended March 31,
	2024		2023
Enterprise	$	46,960	$	70,193
Provider	28,427		28,974
Life Sciences	15,474		17,128
Total Revenue	$	90,861	$	116,295

Other Income

For the three months ended March 31, 2024 and 2023, other income (expense) consisted of the following (in thousands):


	Three Months Ended March 31,
	2024		2023
Re-measurement of contingent consideration	$	294	$	138
Re-measurement of warrant liabilities	85		—
Other	(11)		291
Total other income	$	368	$	429

Accounting Standards Not Yet Adopted

As an emerging growth company (“EGC”), the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are applicable to private companies (that is, those that have not had a registration statement declared effective under the Securities Act of 1933, as amended (the “Securities Act”), or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company has elected to use this extended transition period under the JOBS Act until such time as the Company is no longer considered to be an EGC. The adoption dates discussed below reflect this election.

Income Taxes. In December 2023, the FASB issued ASU No. 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." The new ASU requires public business entities, on an annual basis, to provide a tabular rate reconciliation (using both percentages and reporting currency amounts) of (1) the reported income tax expense (or benefit) from continuing operations, to (2) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal (national) income tax rate of the jurisdiction (country) of domicile using specific categories and separate disclosure for any reconciling items within certain categories that are equal to or greater than a specified quantitative threshold. A public business entity is required to provide an explanation, if not otherwise evident, of the individual reconciling items disclosed, such as the nature, effect, and underlying causes of the reconciling items and the judgment used in categorizing the reconciling items. For each annual period presented, the ASU requires all reporting entities to disclose the year-to-date amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign. It also requires additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The ASU requires that all reporting entities disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign, and income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign.

Table of Contents

Sharecare, Inc.

Notes to Unaudited Consolidated Financial Statements

(Unaudited)

The ASU is effective for public entities for annual periods beginning after December 15, 2024. We are still evaluating the impact on our financial statement disclosures.

Segment Reporting. In November 2023, the FASB issued ASU No. 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." The amendments in this update address the requirement for a public entity to disclose its significant segment expense categories and amounts for each reportable segment. A significant segment expense is any significant expense incurred by the segment, including direct expenses, shared expenses, allocated corporate overhead, or interest expense that is regularly reported to the chief operating decision maker and is included in the measure of segment profit or loss. The disclosure of significant segment expenses is in addition to the current specifically-enumerated segment expenses required to be disclosed, such as depreciation and interest expense. If a public entity does not disclose any significant segment expenses for a reportable segment, it is required to disclose narratively the nature of the expenses used by the chief operating decision maker to manage the segment's operations. The ASU is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. We are still evaluating the impact on our financial statement disclosures as it pertains to the Company’s single reportable segment.

2. Fair Value Measurements

The Company’s financial instruments consist of cash equivalents, accounts receivable, accounts payable, accrued liabilities, warrant liabilities, and contingent consideration liabilities. Cash equivalents are comprised of money market funds stated at amortized cost, which approximates fair value at the balance sheet dates, due to the short period of time to maturity. Accounts receivable, accounts payable, and accrued liabilities are stated at their carrying value, which approximates fair value due to the short time to the expected settlement date. The warrant liabilities and contingent consideration liabilities are recorded at estimated fair value.

The following tables present the fair value hierarchy for assets and liabilities measured at fair value as of March 31, 2024 (in thousands):


	March 31, 2024
	Level 1		Level 2		Level 3		Total Fair Value
Cash equivalents
Money market funds	$	10,470	$	—	$	—	$	10,470
Total cash equivalents at fair value	$	10,470	$	—	$	—	$	10,470

Liabilities
Warrant liabilities	$	317	$	—	$	—	$	317
Contingent consideration – other liabilities	—		—		101		101
Total liabilities at fair value	$	317	$	—	$	101	$	418

The warrants issued during the initial public offering by Falcon Capital Acquisition Corp. “FCAC” and the warrants issued by FCAC simultaneously with its initial public offering in a private placement, are both classified within Level 1 as they are publicly traded and have an observable market price in an active market. Additionally, the warrant liabilities are exercisable for one share of common stock at an exercise price of $11.50.

Contingent consideration is classified within Level 3 as it is valued using certain unobservable inputs. The fair value of the contingent consideration is estimated based on the Company’s stock price and number of shares expected to be issued related to acquisitions in prior years and are estimated using a Monte Carlo simulation with inputs for the Company’s stock price, expected volatility, risk-free rate, first and second earnout hurdles and expected term.

The following is a schedule of changes to the contingent consideration — other liabilities classified as Level 3 for the periods presented (in thousands):

Table of Contents

Sharecare, Inc.

Notes to Unaudited Consolidated Financial Statements

(Unaudited)


December 31, 2023	$	395
Re-measurement of contingent consideration	(294)
March 31, 2024	$	101

3. Balance Sheet Components

Accrued Expenses and Other Current Liabilities

As of March 31, 2024 and December 31, 2023, accrued expenses and other current liabilities consisted of the following (in thousands):


	March 31, 2024		December 31, 2023
Accrued expenses	$	17,304	$	15,546
Accrued compensation	10,506		16,235
Accrued media costs	2,506		5,168
Accrued taxes	1,509		1,837
Operating lease liabilities, current	1,684		1,826
Contract liability due to the Series A Preferred Stockholder	17,496		17,496
Accrued expenses due to the Series A Preferred Stockholder	3,255		6,084
Accrued other	1,256		1,514
Total accrued expenses and other current liabilities	$	55,516	$	65,706

Table of Contents

Sharecare, Inc.

Notes to Unaudited Consolidated Financial Statements

(Unaudited)

4. Goodwill and Other Intangible Assets

Intangible assets and the related accumulated amortization for each class of intangible asset as of March 31, 2024 were as follows (in thousands):


	March 31, 2024
	Cost		Accumulated Amortization		Net		Weighted Average Remaining Life
Definite-lived, intangible assets
Technology – features/content	$	62,926	$	(29,650)	$	33,276	7.2
Trade name	3,549		(2,091)		1,458		3.3
Customer relationships	77,849		(41,121)		36,728		8.2
Internal-use software	189,631		(140,630)		49,001		1.8
Total definite-lived, intangible assets	$	333,955	$	(213,492)	$	120,463

Intangible assets not subject to amortization
Internal-use software projects in process	$	4,770	$	—	$	4,770
Indefinite-lived, trade names	5,030		—		5,030
Total intangible assets not subject to amortization	9,800		—		9,800
Total intangible assets	$	343,755	$	(213,492)	$	130,263

The following tables set forth the changes in the carrying amount of the Company’s goodwill for the period presented (in thousands):


December 31, 2023	$	192,037
Foreign currency translation adjustment	(177)
March 31, 2024	$	191,860

Goodwill and intangible assets deemed to have indefinite lives are not amortized but are subjected to annual tests of impairment. The Company tests goodwill and indefinite-lived intangible assets for impairment annually in the fourth quarter and between annual tests if an event occurs or circumstances change that would indicate that it is more likely than not that the carrying amount may be impaired. The Company initially evaluates qualitative factors to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment is not conclusive, a quantitative assessment of the fair value of a reporting unit is performed to test goodwill for impairment using a combination of income and market approaches. There have been no impairments of goodwill since the Company’s inception.

As a result of the sustained decline in the Company’s stock price and associated market capitalization, the Company performed an impairment test during the first quarter of 2024. The fair value of the reporting units for goodwill impairment testing was determined using both an income approach and market approach. The income approach was based on discounted projected future (debt-free) cash flows for each reporting unit. The discount rates applied to these cash flows were based on the weighted average cost of capital for each reporting unit, which takes market participant assumptions into consideration. For the market approach, we used both the guideline public company and similar transaction methods. The guideline public company method analyzes market multiples of revenue and EBITDA for a group of comparable public companies. Under the similar transactions method, valuation multiples are calculated utilizing actual transaction prices and revenue and EBITDA data from target companies deemed similar to the reporting unit. As a result of the interim test, the fair values of each of our reporting units exceeded their respective book values in excess of approximately 10%, and the Company determined there was no impairment. An increase of 100 basis points in the weighted average cost of capital or a decrease of 100 basis points in annual forecasted revenues would have resulted in a 3% and 9% decline in the fair value, respectively of our reporting units which would not have resulted in impairment.

Table of Contents

Sharecare, Inc.

Notes to Unaudited Consolidated Financial Statements

(Unaudited)

Amortization expense for intangible assets during the three months ended March 31, 2024 and 2023 totaled $12.7 million and $14.0 million, respectively. Amortization expense is included in depreciation and amortization in the Consolidated Statements of Operations and Comprehensive Loss.

The following is a schedule of estimated future amortization expense for intangible assets as of March 31, 2024 (in thousands):


Year ending December 31:
Remainder of 2024	$	33,671
2025	31,239
2026	17,572
2027	10,104
2028	6,932
Thereafter	20,945
Total	$	120,463

5. Income Taxes

As a result of the Company’s history of net operating losses, the Company has provided for a full valuation allowance against its deferred tax assets, with the exception of its German and French operations. For the three months ended March 31, 2024, the Company recognized income tax benefit of less than $0.1 million, primarily due to tax on foreign income. For the three months ended March 31, 2023, the Company recognized income tax benefit of less than $0.1 million, primarily due to tax on foreign income.

6. Common Stock and Stockholders’ Equity

Warrants

In connection with debt and equity financings and certain partnership arrangements, the Company may issue warrants. Warrants classified as liabilities generally vest immediately and are exercisable upon issuance and have an expiration of seven years from the date of issuance. Warrants classified as equity generally vest after three years from the date of issuance and have an expiration of seven years from the date of issuance.

As of March 31, 2024, the following warrants to purchase common stock were issued and outstanding:


Classification	Warrants Outstanding	Exercise Price per Share
Equity	1,278,746	$4.21 - $5.61
Liability	17,433,334	$11.50

The Company has also entered into, and may in the future enter into, contractual arrangements with certain customers and other parties and earnout arrangements in connection with acquisitions that, in each case, provide for the issuance of warrants and/or common stock upon the achievement of specified milestones. As of March 31, 2024, these agreements provide for the issuance of up to 3,238,675 shares of common stock and 6,353,577 warrants to purchase shares of common stock. With respect to these arrangements, there were 52,589 warrants earned but not issued as of March 31, 2024.

Share-based Payments

Stock option and restricted stock unit activity, prices, and values during the three months ended March 31, 2024 are as follows (in thousands, except share and per share amounts):

Table of Contents

Sharecare, Inc.

Notes to Unaudited Consolidated Financial Statements

(Unaudited)


	Options Outstanding						Restricted Stock Units
	Number of Options	Weighted- Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in thousands)		Number of Plan shares outstanding	Weighted-Average Grant Date Fair Value per share
Outstanding as of December 31, 2023	92,218,339	$	3.01	5.87	$	1,256	49,007,766	$	1.93
Granted	—	—					15,089,859	$	1.03
Exercised/Released	(40,278)	$	0.59		$	7	(7,674,699)	$	2.38
Cancelled/Forfeited	(2,685,153)	$	2.40				(661,764)	$	1.85
Outstanding as of March 31, 2024	89,492,908	$	3.03	5.58	$	260	55,761,162	$	1.62
Vested and/or exercisable as of March 31, 2024	73,764,072	$	1.88	5.24	$	260
Vested and/or exercisable as of December 31, 2023	73,902,493	$	1.89	5.49	$	1,256

The intrinsic value is calculated as the difference between the exercise price of the underlying common stock option award and the estimated fair value of the Company’s common stock. Vested but unissued restricted stock units as of March 31, 2024 and December 31, 2023 were immaterial.

Share-based compensation expense for employee and nonemployee options and restricted stock units included in the Consolidated Statements of Operations and Comprehensive Loss is as follows for the three months ended March 31, 2024 and 2023 (in thousands):


	Three Months Ended March 31,
	2024		2023
Cost of revenues	$	204	$	111
Sales and marketing	1,508		828
Product and technology	1,664		1,068
General and administrative	10,468		7,962
Total share-based compensation expense	$	13,844	$	9,969

Additionally, share-based compensation costs, reflected within additional paid-in capital in the Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the three months ended March 31, 2024 and 2023, included approximately $0.2 million and $0.4 million related to capitalizable internally developed software activities, respectively.

On May 31, 2023, each of the principal executive officer, principal financial officer, other named executive officers, and certain eligible employees of the Company voluntarily elected to forgo up to 25% of their cash base salary for the next 12 months, and in lieu thereof received restricted stock units (“RSUs”) with a value equal to the cash amount they elected to forego over the 12-month period. In consideration for forgoing guaranteed cash compensation, each individual will receive an additional number of RSUs with a value equal to 25% of the amount of cash salary they have elected to forgo. The RSUs were issued in June 2023 and will vest in four equal quarterly installments over the next 12 months, subject to the individual’s continued employment. The ability of the named executive officers and other eligible employees to make such election to forgo guaranteed cash compensation and receive RSUs in lieu thereof was approved by the Compensation and Human Capital Committee of the Company’s board of directors. The unvested RSUs are classified as a liability. As of March 31, 2024, there was $0.4 million of unvested RSUs classified as a liability and recorded to accrued expenses and other current liabilities in the Consolidated Balance Sheets. As such, share-based compensation costs, reflected within additional paid-in capital in the Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the three months

Table of Contents

Sharecare, Inc.

Notes to Unaudited Consolidated Financial Statements

(Unaudited)

ended March 31, 2024 does not reflect the cost associated with these awards. Upon vesting of these RSUs, amounts will be reclassified from liability to equity.

7. Commitments and Contingencies

Legal Matters

From time to time, the Company is subject to litigation in the normal course of business. The Company is of the opinion that, based on the information presently available, the resolution of any such legal matters will not have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. The Company has accrued for losses that are both probable and estimable.

We are also party to investigations and legal disputes and losses related to certain matters that are reasonably possible, but at this time, we cannot estimate a loss or range of losses.

8. Related-Party Transactions

Sul América Serviços de Saúde S.A. (Sul América), is a customer of and owns a 49% interest in Sharecare Brasil Servicios de Consultoria, Ltda. As of the year ended December 31, 2023, the Company ended the services contract with this related party and ceased operations of Sharecare Brasil Servicios de Consultoria, Ltda. Revenues recognized for the three-month period ended March 31, 2024 and 2023 from Sul América totaled $0.3 million and $1.3 million, respectively. For the three-month period ended March 31, 2024, the revenues recognized represent variable termination fee revenue, which was previously contrained and for which uncertainty about the variable amount to be received was resolved.

The Series A Preferred Stock is held by a customer that also had an employee serving on the Sharecare Board. During the three month period ended June 30, 2023, the board member ceased employment with the customer. Subsequent to the board member’s termination of employment with the customer, this customer was no longer considered a related party. Revenues recognized for this customer for the three months ended March 31, 2023 totaled $6.2 million. As of December 31, 2023, $13.0 million in receivables were outstanding from this related party.

During the third quarter of 2022, we entered into a revenue contract with the Series A Preferred Stockholder to provide patient advocacy services. We also entered into separate agreements to purchase distinct goods and services. These agreements are now subject to a dispute. Separate from the above disclosed amounts for this related party, revenues recognized related to these distinct services for the three months ended March 31, 2023 totaled $10.6 million. Additionally, revenue for the three months ended March 31, 2023, included $0.4 million of amortization of contract assets. For the three months ended March 31, 2023, cost of sales totaled $10.9 million. Amounts paid under the agreements that were not determined to be distinct were recorded as a reduction of revenues.

As of December 31, 2023, there were $34.3 million in receivables and $51.1 million in accounts payable and accrued expenses recorded in connection with these distinct agreements. Additionally, in 2022 the Company acquired certain intellectual property which was determined to be distinct and recorded an intangible asset, which is being amortized over its estimated useful life. The unamortized balance of intangible asset was $3.1 million as of December 31, 2023. As of March 31, 2024, the receivables, accounts payable, and accrued expenses balances recorded in connection with these distinct agreements remained unchanged.

The Company has a customer that was a related party for the year ended December 31, 2023 due to an affiliation with a member of the Sharecare Board. This member was nominated during the first quarter of 2023 and has subsequently ceased employment with the customer. This customer is no longer considered a related party as of December 31, 2023. As of December 31, 2023, $1.0 million in receivables were outstanding from this related party and revenues recognized for the three months ended March 31, 2023 totaled $0.7 million.

Table of Contents

Sharecare, Inc.

Notes to Unaudited Consolidated Financial Statements

(Unaudited)

9. Net Loss Per Share

Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):


	Three Months Ended March 31,
	2024		2023
Numerator
Net loss	$	(35,144)	$	(35,005)
Less: Net loss attributable to noncontrolling interests in subsidiaries	(57)		(346)
Net loss available to common stockholders	$	(35,087)	$	(34,659)

Denominator
Weighted-average common shares outstanding, basic and diluted	354,208,908		352,923,217
Net loss per share attributable to common stockholders, basic and diluted	$	(0.10)	$	(0.10)

The Company’s potential dilutive securities, which include stock options and restricted stock units, redeemable convertible preferred stock, and contingently issuable shares, have been excluded from the computation of diluted net loss per share for the three-months ended March 31, 2024 and 2023, as they are anti-dilutive and the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common share equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:


	Three Months Ended March 31,
	2024	2023
Stock options and restricted stock units	2,660,077	30,951,366
Redeemable convertible preferred stock	5,000,000	5,000,000

Total	7,660,077	35,951,366

Additionally, stock options of 89.1 million that have exercise prices in excess of the average market price of common shares for the three months ended March 31, 2024 and restricted stock units of 53.5 million as of March 31, 2024 are not included in the calculation of potentially dilutive securities, but could become dilutive in future periods.

For the prior period, stock options of 73.7 million that have exercise prices in excess of the average market price of common shares for the three months ended March 31, 2023 and restricted stock units of 32.5 million as of March 31, 2023 are not included in the calculation of potentially dilutive securities.

10. Subsequent Events

The Company considers events or transactions that occur after the balance sheet date, but before the consolidated financial statements are issued, to provide additional evidence relative to certain estimates or identify matters that require additional disclosures. The Company evaluated subsequent events through, May 9, 2024, the date on which the consolidated financial statements were available to be issued, noting no such material events.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of the financial condition and results of operations of Sharecare, Inc. (for purposes of this section, “the Company,” “Sharecare,” “we,” “us” and “our”) should be read together with the Company’s audited financial statements as of and for the years ended December 31, 2023, 2022, and 2021, together with the related notes thereto, included in our Annual Report on Form 10-K filed with the SEC on March 29, 2024, and Sharecare’s unaudited interim financial statements as of March 31, 2024 and for the three months ended March 31, 2024 and 2023, together with the related notes thereto, included elsewhere in this Quarterly Report on Form 10-Q. Actual results may differ materially from those contained in any forward-looking statements.

Cautionary Statement Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements regarding, among other things, the plans, strategies and prospects, both business and financial, of Sharecare. These statements are based on the beliefs and assumptions of our management. Although we believe that our plans, intentions, and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties, and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates,” “possible,” “continue,” “might,” “potential” or “intends” or similar expressions. Forward-looking statements contained in this report include, but are not limited to, statements regarding our expectations as to:

•our business, operations and financial performance, including:

◦expectations with respect to our financial and business performance, including financial projections and business metrics and any underlying assumptions thereunder;

◦future business plans and growth opportunities, including revenue opportunities available from new or existing clients and expectations regarding the enhancement of platform capabilities and addition of new solution offerings;

◦developments and projections relating to our competitors and the digital healthcare industry;

◦the impact of rising inflation, increasing interest rates, public health emergencies, financial institution disruptions and other macroeconomics factors on our business and the actions we may take in response thereto;

◦our expectations regarding anticipated and future partnerships or other relationships with third parties and future acquisitions;

◦our future capital requirements and sources and uses of cash, including potential share repurchases and our ability to obtain additional capital in the future and fully access our Revolving Facility; and

◦our ability to recognize performance-based revenue;

•our status as an EGC and our intention to take advantage of accommodations available to EGCs under the JOBS Act;

•our ability to regain and maintain compliance with Nasdaq listing standards;

•our success in retaining or recruiting, or changes required in, our officers, key employees or directors, and the success of our workplace globalization efforts; and

•the other estimates and matters described in this Quarterly Reports on Form 10-Q under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

These forward-looking statements are based on information available as of the date of this report, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements include, but are not limited to, those set forth in this report and in the “Risk Factors” section of our Annual Report on Form 10-K filed with the SEC on March 29, 2024. For example, the Company’s expectations regarding future performance assume business currently under contract and satisfaction by our customers of their contractual obligations under those agreements, which is not within the

Table of Contents

Company’s control. If a customer fails to satisfy its contractual obligations, actual results could be negatively impacted. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Should one or more of these risks or uncertainties materialize, or should any of the underlying assumptions prove incorrect, actual results may vary in material respects from those expressed or implied by these forward-looking statements. You should not place undue reliance on these forward-looking statements.

Overview

We are a leading digital healthcare company that helps people access, navigate and unify resources to improve their health and well-being in one place, regardless of where they are in their health journey. Our comprehensive and data-driven interoperable ecosystem is designed to help people, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by enabling positive behavior change. Driven by our philosophy that we are “all together better”, at Sharecare, we are committed to supporting each individual through the lens of their personal health and ensuring high-quality care is more accessible and affordable for everyone.

Our digital first ecosystem is centered on the person. We believe everyone’s health and well-being is inherently interconnected. Just as a person’s physical health is inextricably linked to their mental and emotional health, an individual’s health is also connected to a greater collective that includes their employer, providers, insurers, colleagues, family, friends, and local communities. However, these groups have historically remained disconnected with various stakeholders providing potentially hundreds of fragmented point solutions, each addressing only one or two specific health-related objectives. By integrating fragmented point solutions and bringing together disparate stakeholders across the healthcare ecosystem into one connected, interoperable virtual care platform, we believe that we can fulfill the role of a unifier and leverage smartphone technology to foster a frictionless user-friendly experience that engages people across the dynamic continuum of their healthcare needs. We have built our platform into what we believe is the most comprehensive and seamless experience currently available in the digital healthcare space.

Our business combines business-to-business and direct-to-consumer sales models and functions on a more distinctive business-to-business-to-person model. Focusing on the individual, we aim to provide a solution that we believe is more comprehensive than other digital platforms by bringing together scientifically validated clinical programs and engaging content to deliver a personalized experience for our members, whether they come to us by way of the workplace, the exam room, or the living room.

We derive revenue from multiple stakeholders and while we are focused on the individual’s unique experience, our platform is purpose-built to seamlessly connect stakeholders to the health management tools they need to drive engagement, establish sustained participation, increase satisfaction, reduce costs, and improve outcomes. As we expand our offerings and look to further develop our technologies, we continue to consider the distinct needs of each client channel as well as opportunities to better connect and cross-sell while we grow and integrate our solutions into one seamless platform.

Our one platform can be disaggregated into three client channels:

•Enterprise Solutions: Our enterprise channel includes a range of clients — from large employers and healthcare systems to government agencies and health plans — that use our platform to engage with their populations, dynamically measure the impact of that engagement, and efficiently deliver health and wellness services.

•Provider Solutions: Our suite of data and information-driven solutions for healthcare providers is tailored to improve productivity and efficiency and enhance patient care and management while upholding the latest compliance, security, and privacy standards.

•Life Sciences: Our robust platform and suite of digital products and medical expert knowledge provides members with personalized information, programs, and resources to improve their health and well-being, and affords sponsors the opportunity to integrate their brands into Sharecare’s consumer experience in a highly contextual, relevant, and targeted environment.

Key Factors and Trends Affecting our Operating Performance

Our financial condition and results of operations have been, and will continue to be, affected by a number of factors, including our success with respect to the following:

Table of Contents

•Expanding our Footprint. We believe that our current client base represents a small fraction of potential clients that could benefit from our highly differentiated solutions. We will continue to invest in our sales and marketing efforts and leverage our partner relationships to continue to acquire new clients, including individuals, providers, employers, health plans, government organizations, and communities.

•Expanding our Existing Client Relationships. We also believe that there is significant opportunity to generate growth by maintaining and expanding our relationships with existing clients, including:

•increasing engagement and enrollment of eligible members with our existing enterprise clients through continued sales and marketing efforts, including targeted next-generation digital modeling and marketing, and capitalizing on insights from claims ingestion (the process by which we receive and process information from our clients), population risk stratification and incentives management;

•facilitating intervention with Sharecare+, our high-touch, digital-first advocacy driving high quality experience, care, and value support;

•promoting our marketplace of existing targeted digital therapeutics to close gaps in care in high-cost areas, which we believe represents a $1 billion revenue opportunity within our currently contracted clients; and

•expanding our relationships with our top 25 provider clients with an opportunity to extend our provider products and services to more than 8,500 additional healthcare sites.

•Offering Additional Solutions. We believe there is significant opportunity to cross-sell our provider solutions to existing accounts, including deploying our value-based care solution to approximately 6,000 health system clients.

•Growing our Platform. We are constantly evaluating the marketplace for ways to broaden and enhance our client and member experience, improve clinical results, and increase revenue through product innovation, partnerships, and acquisitions. We intend to continue to leverage our expertise through adding digital therapeutics partnerships as well as the acquisition of products and services that are directly relevant to our existing clients. Additionally, we believe our strong and embedded client relationships provide us with unique perspectives into their evolving needs and the needs of their populations. For example, in January 2023, we launched Sharecare+, our digital-first, comprehensive advocacy solution designed to deliver value through benefits navigation, clinical engagement, virtual care, and chronic case and utilization management.

•Evolving our Products to Cater to an Evolving Industry. As the digital healthcare industry grows, we closely monitor evolving consumer trends and organizations’ needs so that we may adapt our platform to better suit our clients’ demands. Since March 2020, the COVID-19 pandemic greatly accelerated the demand for virtual care solutions and resulted in rapid growth and increased adoption of digital health technologies, which Sharecare was in a unique position to undertake. By building on our deep expertise in handling and managing mass health data, we launched a suite of distinct but complementary digital tools and programs to address the evolving emotional, educational, clinical, and operational challenges introduced by the pandemic. We intend to continue to look for opportunities to leverage our platform and expertise to provide first-mover solutions to evolving and future demands in the digital healthcare industry.

•Acquisitions. We believe that our proven track record of successful acquisitions coupled with the flexibility and capabilities of our platform positions us to continue opportunistically pursuing attractive M&A opportunities. We believe this potential is further accentuated by our multiple client channels and constantly expanding member base. Future acquisitions could drive value and growth in a host of ways, including access to new customers and potential cross-sell opportunities; unlocking new customer channels or geographies; adding new solutions to serve our existing client base; and adding new capabilities to enhance our existing solution offering or the efficiency of our platform. In addition, we believe our acquisition track record demonstrates our ability to realize synergies and optimize performance of potential M&A partners.

•Globalization Efforts and Cost Savings. Through our globalization efforts, we believe there is opportunity to achieve approximately $30 million in annualized cost savings, which will include both operating and capitalized expense reductions. These efforts across our Provider and Enterprise channels have begun to yield cost savings, which began in the first quarter of 2023 and continue to increase as we expect the global shared service center to become fully operational during the first half of 2024.

•Contract Dispute. We are currently in a contract dispute with a customer over an attempted termination by that party of a contract we believe is non-terminable, with remaining fees owed to the Company totaling $50 million over the life of the contract. The counterparty has withheld payment of outstanding invoices and has indicated it

Table of Contents

does not intend to make any additional payments to the Company under the contract. We believe the contract unambiguously prohibits termination by the counterparty or the withholding of any fees payable to the Company and counterparty’s failure to remit payments and repudiation of future payment obligations constitutes a clear and material breach of the contract. Therefore, we have disputed the purported termination and are vigorously pursuing recovery of the amounts owed under the contract plus damages from the counterparty. We also have other commercial contracts related to advocacy services with certain subsidiaries of the same party that we believe have been breached by such subsidiaries, and we are in the process of taking action to enforce our rights and remedies under the applicable contracts. That contract dispute relates to pricing, amounts owed under the contracts and related matters and is not related to issues regarding the delivery of services by Sharecare. However, it became unfeasible for us to continue to deliver contracted services during the fourth quarter of 2023, which has had a negative impact on our financial results. These disputes are expected to continue to impact our financial results, and we are unable to estimate the probability of a favorable or unfavorable outcome with respect to the disputes at this time. We also expect to incur additional costs as we pursue our legal rights and remedies.

Components of Our Results of Operations

Revenue

The enterprise channel provides employers and health plans with health management programs for large populations, including digital engagement, telephonic coaching, incentives, biometrics, digital therapeutics, home health offerings, advocacy solutions, and subscriptions to the Sharecare platform. Revenue is recognized on a per member per month (“PMPM”) basis or as services are provided. Provider revenue is primarily based on health document requests filled in the health data services business line, as well as subscription fees for various technology related services that assist providers with performance and maximizing reimbursement. Life sciences revenue is generated mostly through ad sponsorships to Sharecare’s extensive member database.

Costs of Revenue

Costs of revenue consist of costs incurred in connection with delivering our various revenue generating activities. Costs are primarily driven by volumes related to requests, engagement, and incentive fulfillment. The major components that make up our cost of revenue are personnel costs to support program delivery as well as customer service along with share-based compensation for employees engaged in delivering products and services to customers, data management fees related to file processing, and variable fees to deliver specific services that may require third party vendors, direct marketing, fulfillment, transaction fees, costs associated with exiting a contract, settlement of contractual obligations, or other costs that can be reduced to offset a decline in revenue. Because our growth strategy includes substantial opportunity to scale low-personnel cost products, we would anticipate future revenue to grow at a faster rate than cost of revenue as those low-personnel cost products mature. Costs of revenue do not include depreciation or amortization, which are accounted for separately.

Sales and Marketing Expenses

Sales and marketing expenses consist primarily of employee-related expenses, including salaries, benefits, commissions, employment taxes, travel, globalization efforts, and share-based compensation costs for our employees engaged in sales, account management, marketing, public relations and related support. In addition, these expenses include marketing sponsorships and engagement marketing spend. These expenses exclude any allocation of occupancy expense and depreciation and amortization.

We expect our sales and marketing expenses to fluctuate as we strategically invest to expand our business while also cutting back on marketing sponsorships. As we scale our sales and marketing personnel in the medium- to long-term, we expect these expenses to fluctuate in both absolute dollars and as a percentage of revenue.

Product and Technology Expenses

Product and technology expenses include personnel and related expenses for software engineering, information technology infrastructure, business intelligence, technical account management, project management, security, product development, globalization efforts, and share-based compensation. Product and technology expenses also include indirect hosting and related costs to support our technology, outsourced software, and engineering services. Our technology and development expenses exclude any allocation of occupancy expense and depreciation and amortization.

We continue to invest in the development of our technology platform with a more focused effort on the globalization of our technology teams, which has helped to reduce overall spend. This effort has resulted in significant decreases in both operating expenses and capital expenditures. Our technology and development expenses may fluctuate as a percentage of our total revenue from period to period partially due to the timing and extent of our technology and development expenses.

Table of Contents

General and Administrative Expenses

General and administrative expenses include personnel and related expenses for our executive, finance, legal, and human resources departments plus all indirect staff in the divisions not attributable to service delivery, sales and marketing, product and technology and our globalization efforts. They also include professional fees, share-based compensation, settlement of legal obligations, lease termination expense, enterprise resource planning implementation costs, acquisition related costs, rent, utilities and maintenance-related costs. Our general and administrative expenses exclude any allocation of depreciation and amortization. Our general and administrative expenses may fluctuate as a percentage of our total revenue from period to period partially due to the timing and extent of our general and administrative expenses.

Depreciation and Amortization

Depreciation and amortization consists primarily of depreciation of fixed assets, amortization of software, amortization of capitalized software development costs and amortization of acquisition-related intangible assets.

Interest Income

Interest income primarily relates to interest recognized on our money market and overnight interest-bearing accounts.

Interest Expense

Interest expense primarily relates to interest and fees incurred on our line of credit and the amortization of debt issuance costs.

Other Income

Other income primarily relates to the guarantee expense of a standby letter of credit for a third party non-profit organization and changes in the fair value of contingent consideration and warrant liabilities.

Table of Contents

Results of Operations

Comparison of the Three Months Ended March 31, 2024 and 2023

The following table presents our unaudited Consolidated Statement of Operations for the three months ended March 31, 2024 and 2023, and the percentage change between the two periods:


	Three Months Ended March 31,
(in thousands)	2024		2023		$ Change		% Change
Revenue	$	90,861	$	116,295	$	(25,434)	(22)	%
Costs and operating expenses:
Costs of revenue (exclusive of amortization and depreciation below)	51,121		67,890		(16,769)		(25)	%
Sales and marketing	13,558		15,348		(1,790)		(12)	%
Product and technology	14,544		20,808		(6,264)		(30)	%
General and administrative	34,907		34,121		786		2	%
Depreciation and amortization	13,331		14,781		(1,450)		(10)	%
Total costs and operating expenses	127,461		152,948		(25,487)		(17)	%
Loss from operations	(36,600)		(36,653)		53		—	%
Other income (expense)
Interest income	1,274		1,680		(406)		(24)	%
Interest expense	(217)		(430)		(213)		(50)	%
Other income	368		429		(61)		14	%
Total other income (expense)	1,425		1,679		(254)		15	%
Net loss before taxes	(35,175)		(34,974)		(201)		(1)	%
Income tax benefit	31		(31)		62		(200)	%
Net loss	(35,144)		(35,005)		(139)		—	%
Net loss attributable to noncontrolling interest in subsidiaries	(57)		(346)		289		(84)	%
Net loss attributable to Sharecare, Inc.	$	(35,087)	$	(34,659)	$	(428)	(1)	%

____________

n.m. — Percentage change not meaningful

Revenue

Revenue decreased $25.4 million, or 22%, from $116.3 million for the three months ended March 31, 2023 to $90.9 million for the three months ended March 31, 2024. Overall, the revenue decrease was attributable mostly to our Enterprise channel, including a contractual dispute with a large advocacy customer as outlined in the footnotes of the Company’s financial statements and as discussed above under Key Factors and Trends Affecting our Operating Performance - Contract Dispute. Additionally, revenue decreased due to reduced supplemental hours in our home health business, the ceasing of our Brazil operations, and the expiration of two payor customers in the population health line of business.

The channel revenue changed as follows: enterprise channel decreased by $23.2 million (from $70.2 million for 2023 to $47.0 million for 2024), the provider channel decreased by $0.6 million (from $29.0 million for 2023 to $28.4 million for 2024) and the life sciences channel decreased by $1.6 million (from $17.1 million for 2023 to $15.5 million for 2024). The decrease in the enterprise channel of 33% was attributable to a contractual dispute with a large advocacy customer, expiration of two payor customers and reduced supplemental staffing hours in home health. The provider channel decrease of 2% was primarily attributable to seasonal timing of audit volumes that were delivered earlier in the prior year. The life sciences channel decreased 9% due to an expiring patent for a large brand and the expected decrease of Smart Omix deliverables.

Table of Contents

Costs of Revenue

Costs of revenue decreased $16.8 million, or 25%, from $67.9 million for the three months ended March 31, 2023 to $51.1 million for the three months ended March 31, 2024. The decrease was primarily associated with lower revenue due to the aforementioned advocacy contract dispute along with cost optimization in the Provider channel.

Sales and Marketing

Sales and marketing expense decreased $1.8 million, or 12%, from $15.3 million for the three months ended March 31, 2023 to $13.6 million for the three months ended March 31, 2024. The decrease was primarily due to reduced marketing sponsorship fees, along with reduced third party application and consulting expense, and lower travel and sales event expenses.

Product and Technology

Product and technology expenses decreased $6.3 million, or 30%, from $20.8 million for the three months ended March 31, 2023 to $14.5 million for the three months ended March 31, 2024. The decrease was attributable to globalization of technology operations, reduced severance costs, the wind down of our Brazil joint venture, and the discontinuation of up front research and development amortization as recognized in prior periods.

General and Administrative

General and administrative expense increased $0.8 million, or 2%, from $34.1 million for the three months ended March 31, 2023 to $34.9 million for the three months ended March 31, 2024. General and administrative expense increased due to an increase in share-based compensation of $2.5 million, which was offset by cost reduction efforts of our facility lease footprint, lower business insurance, and lower content/video production.

Depreciation and Amortization

Depreciation and amortization decreased $1.5 million, or 10%, from $14.8 million for the three months ended March 31, 2023 to $13.3 million for the three months ended March 31, 2024. The decrease was primarily related to the lower capitalization rates of internal use software development as compared to the prior year.

Non-GAAP Financial Measures

In addition to our financial results determined in accordance with U.S. GAAP, we believe the non-GAAP measures adjusted EBITDA, adjusted net loss, and adjusted loss per share, are useful in evaluating our operating performance. We use adjusted EBITDA, adjusted net loss, and adjusted loss per share to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that these non-GAAP financial measures, when taken together with the corresponding GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. In particular, we believe that the use of adjusted EBITDA, adjusted net loss, and adjusted loss per share is helpful to our investors as they are metrics used by management in assessing the health of our business and our operating performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as a tool for comparison. The reconciliations of adjusted EBITDA, adjusted net loss, and adjusted loss per share to net loss, the most directly comparable financial measure stated in accordance with GAAP, are provided below. Investors are encouraged to review the reconciliations and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA

Adjusted EBITDA is a key performance measure that management uses to assess our operating performance. Because adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes.

We calculate adjusted EBITDA as net loss adjusted to exclude (i) depreciation and amortization, (ii) interest income, (iii) interest expense, (iv) income tax (benefit) expense, (v) other income (non-operating), (vi) share-based compensation, (vii) warrants issued with revenue contracts, (viii) amortization of non-cash payment for research and development, (ix) non-operating, non-recurring costs, (x) reorganizational and severance costs, and (xi) acquisition-related costs. We do not view the items excluded as representative of normal, recurring, cash operating expenses necessary to operate our lines of business and services.

Table of Contents

Non-operating, non-recurring costs for the three months ended March 31, 2024 include costs related to legal matters involving prior acquisitions and in connection with the contractual obligation with a financially distressed vendor and are recorded in general and administrative operating expense.

Non-operating, non-recurring costs for the three months ended March 31, 2023 include costs of our enterprise resource planning (“ERP”) system implementation, costs of contractual obligations associated with a financially distressed vendor, and costs related to legal matters. The ERP and legal matter costs are recorded in general and administrative operating expense and the financially distressed vendor costs are recorded in cost of revenue in the Consolidated Statement of Operations and Comprehensive Loss for each respective period presented.

Legal matter costs include attorney fees associated with a dispute that arose from a prior acquisition, attorney fees associated with the submission of an unsolicited acquisition offer as filed in the Schedule 13D with the SEC on October 11, 2023, and attorney fees related to contractual obligations associated with a financially distressed vendor. These matters have unique facts and circumstance that are not directly related to our operations. We do not consider these costs to be normal, recurring, cash operating expenses necessary to operate our business.

The ERP implementation is viewed as a transformational undertaking due to the extensive scope and inherent change management involved to transition to a new single-solution ERP system from the disparate legacy systems. These costs consist of internal and third-party costs of the ERP implementation and do not include capitalized costs, depreciation and/or amortization, or costs to support or maintain software applications or systems once they are in productive use. The ERP system was fully implemented as planned in 2023, and such costs are not expected to recur in the foreseeable future. We do not consider these costs to be normal, recurring, cash operating expenses necessary to operate our business.

Financially distressed vendor costs include financial support from us to a vendor in response to the vendor’s financial difficulties, which absent such support would have resulted in an interruption of our service to our customers. Because we are committed to providing uninterrupted service to our customers, and to minimizing the risk of such a disruption, we made additional, advance payments to the vendor beyond those that were due to the vendor in association with services procured from the vendor. We ceased procuring services from the vendor in Q2 2023 and subsequent to that period no further amounts were paid. Because the costs of the additional payments made to the vendor were incremental to the costs incurred by us to deliver service to our customers, we do not consider them to be normal, recurring, cash operating expenses necessary to operate our business.

Reorganizational and severance costs are a component of our Globalization Efforts and Cost Savings as described in Key Factors and Trends Affecting our Operating Performance. These costs are due to efforts to globalize and centralize our workforce through the creation of the global shared service center which is expected to be fully operational during the first half of 2024. We have never had a global shared service center and view this undertaking as outside the scope of normal operations. Costs include salary, benefits, equity and bonus compensation, and other employee costs for those who were identified to be terminated. These costs were recorded in sales and marketing, product and technology, and general and administrative operating expenses in the Consolidated Statement of Operations and Comprehensive Loss for the periods presented, based on the employee’s respective job function. Because these costs are part of a specific and unprecedented initiative, we do not consider these expenses to be normal, recurring, cash operating expenses necessary to operate our business.

Certain prior period adjusted EBITDA add-back amounts have been reclassified to new add-back line items in order to conform to the current period presentation and to more accurately describe the nature of the amounts year-over-year.

The following table presents a reconciliation of adjusted EBITDA from the most comparable GAAP measure, net loss, for the three months ended March 31, 2024 and 2023 (in thousands):

Table of Contents


	Three Months Ended March 31,
	2024		2023
Net loss	$	(35,144)	$	(35,005)
Add:
Depreciation and amortization	13,331		14,781
Interest income	(1,274)		(1,680)
Interest expense	217		430
Income tax (benefit) expense	(31)		31
Other income (non-operating)	(368)		(429)
Share-based compensation	13,596		9,969
Warrants issued with revenue contracts	28		14
Amortization of non-cash payment for research and development	—		1,190
Non-operating, non-recurring costs(a)	2,162		1,716
Reorganizational and severance costs(b)	3,345		9,030
Acquisition-related costs	1,413		558
Adjusted EBITDA(c)(d)	$	(2,725)	$	605

____________

(a)For the three months ended March 31, 2024, primarily represents costs related to legal matters involving prior acquisitions for $1.7 million and in connection with the contractual obligation with a financially distressed vendor of $0.4 million. For the three months ended March 31, 2023, primarily represents costs related to the ERP implementation of $0.4 million, contractual obligations with a financially distressed vendor of $0.4 million, and legal matters of $0.2 million.

(b)For the three months ended March 31, 2024, primarily represents costs related to globalizing the Company's workforce of $2.9 million and severance of $0.4 million. For the three months ended March 31, 2023, primarily represents costs related to globalizing the Company's workforce of $8.3 million and severance of $0.8 million.

(c)Includes non-cash amortization associated with contract liabilities recorded in connection with acquired businesses.

(d)Effective September 30, 2023, we no longer exclude costs associated with exiting a contract and lease terminations from our computation of adjusted EBITDA. For the three months ended March 31, 2023 these costs totaled $0.7 and $0.8 million, respectively.

Adjusted Net Loss

Adjusted net loss is a key performance measure that management uses to assess our operating performance. Because adjusted net loss facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes and to evaluate our performance.

We calculate adjusted net loss as net loss attributable to Sharecare, Inc. adjusted to exclude (i) amortization of acquired intangibles, (ii) amortization of deferred financing fees, (iii) change in fair value of warrant liability and contingent consideration, (iv) share-based compensation, (v) warrants issued with revenue contracts, (vi) amortization of non-cash payment for research and development, (vii) non-operating, non-recurring costs, (viii) reorganizational and severance costs, and (ix) acquisition-related costs. We do not view the items excluded as representative of normal, recurring, cash operating expenses necessary to operate our lines of business and services.

See Adjusted EBITDA above for the discussion of the nature of costs underlying the categories of net costs associated with exiting a contract, non-operating, non-recurring costs, and reorganizational and severance costs.

Certain prior period adjusted net loss add-back amounts have been reclassified to new add-back line items in order to conform to the current period presentation and to more accurately describe the nature of the amounts year-over-year.

Adjusted Loss Per Share

Table of Contents

Adjusted loss per share is a key performance measure that management uses to assess our operating performance. Because adjusted loss per share facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes and to evaluate our performance.

We calculate adjusted loss per share as adjusted net loss, as defined above, divided by the number of weighted average common shares outstanding - basic and diluted. We do not view the items excluded as representative of normal, recurring, cash operating expenses necessary to operate our lines of business and services.

The following table presents a reconciliation of adjusted net loss and adjusted loss per share from the most comparable GAAP measure, net loss, for the three months ended March 31, 2024 and 2023 (in thousands, except share numbers and per share amounts):


	Three Months Ended March 31,
	2024		2023
Net loss attributable to Sharecare, Inc.	$	(35,087)	$	(34,659)
Add:
Amortization of acquired intangibles(a)	1,599		1,632
Amortization of deferred financing fees	—		31
Change in fair value of warrant liability and contingent consideration	(379)		(138)
Share-based compensation	13,596		9,969
Warrants issued with revenue contracts	28		14
Amortization of non-cash payment for research and development	—		1,190
Non-operating, non-recurring costs(b)	2,162		1,716
Reorganizational and severance costs(c)	3,345		9,030
Acquisition-related costs	1,413		558
Adjusted net loss(d)(e)	$	(13,323)	$	(10,657)

Weighted-average common shares outstanding, basic and diluted	354,208,908		352,923,217

Loss per share	$	(0.10)	$	(0.10)
Adjusted loss per share	$	(0.04)	$	(0.03)

____________

(a)Represents non-cash expenses related to the amortization of intangibles in connection with acquired businesses.

(b)For the three months ended March 31, 2024, primarily represents costs related to legal matters involving prior acquisitions for $1.7 million and in connection with the contractual obligation with a financially distressed vendor of $0.4 million. For the three months ended March 31, 2023, primarily represents costs related to the ERP implementation of $0.4 million, contractual obligations with a financially distressed vendor of $0.4 million, and legal matters of $0.2 million.

(c)For the three months ended March 31, 2024, primarily represents costs related to globalizing the Company's workforce of $2.9 million and severance of $0.4 million. For the three months ended March 31, 2023, primarily represents costs related to globalizing the Company's workforce of $8.3 million and severance of $0.8 million.

(d)The income tax effect of the Company’s non-GAAP reconciling items are offset by valuation allowance adjustments of the same amount given the Company is in a full valuation allowance position.

(e)Effective September 30, 2023, we no longer exclude costs associated with exiting a contract and lease terminations from our computation of adjusted EBITDA. For the three months ended March 31, 2023 these costs totaled $0.7 and $0.8 million, respectively.

Table of Contents

Liquidity and Capital Resources

We measure liquidity in terms of our ability to fund the cash requirements of our business operations, including working capital and capital expenditure needs, share repurchases, contractual obligations and other commitments, with cash flows from operations and other sources of funding. Our ability to expand and grow our business will depend on many factors, including our working capital needs and the evolution of our operating cash flows.

We had $100.3 million in cash and cash equivalents as of March 31, 2024. Our principal commitments as of March 31, 2024 consist of operating leases and purchase commitments. The Company maintains its Senior Secured Credit Agreement. As of March 31, 2024, there was $53.9 million available for borrowing under the Revolving Facility.

We believe our cash on hand will be sufficient to meet our operating cash flow, working capital, capital expenditure requirements, and fund share repurchases in the short-term (i.e., the 12 months from the date of this Quarterly Report on Form 10-Q). Our long-term liquidity (i.e., more than 12 months from the date of this Quarterly Report on Form 10-Q) needs include cash necessary to support our business growth and contractual commitments. We believe that the potential financing capital available to us in the future is sufficient to fund our long-term liquidity needs, however, we are continually reviewing our capital resources to determine whether we can meet our short- and long-term goals and we may require additional capital to do so. We may also need additional cash resources due to potential changes in business conditions or other developments, including unanticipated regulatory developments, significant acquisitions, and competitive pressures. We expect our capital expenditures and working capital requirements to continue to increase in the immediate future as we seek to expand our solution offerings. To the extent that our current resources are insufficient to satisfy our cash requirements, we may need to seek additional equity or debt financing. If the needed financing is not available, or if the terms of financing are less desirable than we expect, we may be forced to decrease our level of investment in new product offerings and related marketing initiatives or to scale back our existing operations, which could have an adverse impact on our business and financial prospects.

The following table summarizes our cash flow activities for the periods presented:


	Three Months Ended March 31,
(in thousands)	2024		2023
Net cash used in operating activities	$	(19,591)	$	(23,498)
Net cash used in investing activities	$	(5,186)	$	(5,174)
Net cash (used in) provided by financing activities	$	(3,045)	$	522

Operating Activities

Net cash used in operating activities for the three months ended March 31, 2024 was $19.6 million, a decrease of $3.9 million from $23.5 million of net cash used in operating activities for the three months ended March 31, 2023. Cash used during this period included the $35.1 million net loss for the three months ended March 31, 2024, offset by non-cash items of $27.3 million, which were primarily attributable to depreciation and amortization expense, and share-based compensation. In addition, changes in operating assets and liabilities of $11.7 million resulted in net cash used, attributable to accounts receivable, net, prepaid expense and other assets, and accounts payable and accrued expenses.

Investing Activities

Net cash used in investing activities for the three months ended March 31, 2024 was $5.2 million compared to $5.2 million of net cash used in investing activities for the three months ended March 31, 2023. Cash outflows increased for capitalized internal-use software costs offset by a reduction in cash outflows for purchases of property and equipment.

Financing Activities

Net cash used in financing activities for the three months ended March 31, 2024 was $3.0 million, primarily due to payments for shares repurchased of $2.8 million related to taxes paid in association with vesting restricted stock units.

Net cash provided by financing activities for the three months ended March 31, 2023 was $0.5 million, primarily due to cash received from the proceeds from exercised common stock options of $1.0 million and offset by payments on financing lease obligations of $0.4 million.

Contractual Obligations

There were no material changes to contractual obligations since our Annual Report on Form 10-K filed with the SEC on March 29, 2024.

Table of Contents

Financing Arrangements

Senior Secured Credit Agreement

The Company’s senior secured revolving credit facility (the “Revolving Facility”) is governed by a Credit Agreement, dated as of March 9, 2017 (as amended, the “Senior Secured Credit Agreement”), among the Company, certain subsidiaries of the Company, as borrowers (the “Borrowers”), the lenders named therein and Wells Fargo Bank, National Association, as administrative agent. On February 10, 2023, the company renewed its Senior Secured Credit Agreement. The Senior Secured Credit Agreement was due to mature on February 10, 2023 and the Company entered into the Ninth Amendment to the Senior Secured Credit Agreement which extends the maturity date of the Senior Secured Credit Agreement to February 10, 2026. The total commitments under the Revolving Facility remain unchanged at $60.0 million as a result of the Ninth Amendment but the sub-limit for letters of credit has increased from $10.0 million to $15.0 million. Availability under the Revolving Facility is generally subject to a borrowing base based on a percentage of applicable eligible receivables. Borrowings under the Revolving Facility bear interest at a rate equal to, at the applicable Borrower’s option, either (a) a base rate plus a margin of 0.75%, or (b) the 1, 3, or 6-month Secured Overnight Financing Rate (SOFR) plus 1.75%. The Ninth Amendment amends other terms of the existing Senior Secured Credit Agreement, including eliminating minimum liquidity and minimum EBITDA covenants, increased thresholds for certain permitted transactions, modifications to reporting and other changes.

The Senior Secured Credit Agreement contains a number of customary affirmative and negative covenants and we were in compliance with those covenants as of March 31, 2024. As of March 31, 2024, there were $0.6 million borrowings outstanding under the Revolving Facility.

Critical Accounting Estimates

Our financial statements are prepared in accordance with GAAP. The preparation of the consolidated financial statements in conformity with GAAP requires management to make a number of estimates and assumptions relating to the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We evaluate our significant estimates on an ongoing basis, including, but not limited to, goodwill, revenue recognition, share-based compensation, and income taxes. We base our estimates on historical experience, known trends, and other market-specific or relevant factors that we believe to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.

We believe that the accounting policies described below involve a significant degree of judgment and complexity. Accordingly, we believe these are the most critical to aid in fully understanding and evaluating our consolidated financial condition and results of operations. For further information, see Note 1 to Sharecare’s consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Revenue Recognition

Revenue is recognized when control of the promised good or service is transferred to the client, in an amount that reflects the consideration we expect to be entitled to in exchange for that good or service. Sales and usage-based taxes are excluded from revenue. We serve a diverse group of clients. We are the principal in all outstanding revenue arrangements except for CareLinx. CareLinx has B2C and B2B2C service lines for which CareLinx is generally the agent and we recognize the commission revenue based on the amount billed using the “as-invoiced” practical expedient.

Enterprise Revenue

The enterprise channel provides employers and health plans with health management programs for large populations, including digital engagement, telephonic coaching, incentives, biometrics, digital therapeutics, home care health offerings, advocacy solutions, and subscriptions to the Sharecare platform. Revenue is recognized on a PMPM basis or as services are provided. Member participation fees are generally determined by multiplying the contractually negotiated member rate by the number of members eligible for services during the month. Member participation rates are established during contract negotiations with clients, often based on a portion of the value the programs are expected to create. Contracts with health plans, health care systems and government organizations generally range from three to five years with several comprehensive strategic agreements extending for longer periods. Contracts with larger employer clients typically have two-to-four-year terms.

Health management program contracts often include a fee for the subscription of the Sharecare digital platform and various other platforms under doc.ai, which may also be sold on a stand-alone basis. These services allow members to access Sharecare’s proprietary mobile application with a comprehensive suite of health and wellness management programs, content, and tools. Revenue is recognized on a per member or a fixed fee basis as the services are provided.

Table of Contents

Sharecare’s Blue Zones Project is a community well-being improvement initiative designed to change the way people experience the world around them by encouraging and promoting better lifestyle choices, such as commuting, eating, and social habits. Because healthier environments naturally nudge people toward healthier choices, Blue Zones Project focuses on influencing the Life Radius®, the area close to home in which people spend 90% of their lives. Blue Zones Project best practices use people, places, and policy as levers to transform those surroundings. These contracts normally include two performance obligations, the discovery period and the subsequent content delivery, for each year of engagement. The revenue is recognized based on the relative standalone selling price of the performance obligations evenly over time. These contracts do not include termination clauses and often have two-to-four-year terms.

Sharecare’s doc.ai offering unlocks the value of health data through licensing artificial intelligence modules and through the creation of products for a portfolio of clients including payors, pharma, and providers. These contracts generally include two performance obligations. The software license and maintenance/support are considered one series of distinct performance obligations and professional services is considered a separate distinct performance obligation. Revenue is recognized for all identified performance obligations as services are delivered.

Sharecare’s CareLinx offerings are focused on connecting caregivers with facilities or individuals that are in need of additional support. These services are generally considered a series of distinct performance obligations. Revenue is recognized for all identified performance obligations as billed using the “as-invoiced” practical expedient.

Certain contracts place a portion of fees at risk based on achieving certain performance metrics, such as cost savings, and/or clinical outcomes improvements (performance-based). We use the most likely amount method to estimate variable consideration for these performance guarantees. We include in the transaction price some, or all, of an amount of a variable consideration amount only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. We utilize customer data to measure performance.

In the event that performance levels are not met by the end of the measurement period, typically one year, some or all of the performance-based fees are required to be refunded. During the settlement process under a contract, which generally occurs six to eight months after the end of a contract year, performance-based fees are reconciled and settled.

Clients are generally billed monthly for the entire amount of the fees contractually due for the prior month’s enrollment, which typically includes the amount, if any, that is performance-based and may be subject to refund should performance targets not be met. Fees for participation are typically billed in the month after the services are provided. Deferred revenues arise from contracts that permit upfront billing and collection of fees covering the entire contractual service period, generally six months to a year. A limited number of contracts provide for certain performance-based fees that cannot be billed until after they are reconciled with the client.

Provider Revenue

Our provider channel revenue is primarily based on the volume of health document requests fulfilled and recognized upon satisfactory delivery to the client. In addition, provider revenue is derived from subscription fees for various technology-related services that assist providers with efficiency and productivity and enhanced patient care. Subscription fees are recognized ratably over the contractual period.

Life Sciences Revenue

Our life sciences channel generates revenue mostly through ad sponsorships and content delivery. Content delivery revenue is recognized when the content is delivered to the client. Ad sponsorship revenue is recognized when the contractual page views or impressions are delivered and the transaction has met the criteria for revenue recognition.

Certain customer transactions may contain multiple performance obligations that may include delivery of content, page views, and ad sponsorship over time. To account for each of these elements separately, the delivered elements must be capable of being distinct and must be distinct in the context of the contract.

Goodwill

Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination. Goodwill is tested for impairment at the reporting unit level, which is the same or one level below the operating segment. We have one operating segment and two reporting units. We identify our reporting units by assessing whether there are components of our operating segment which constitute businesses for which discrete financial information is available and reviewed regularly by the segment managers and consider whether such components should be aggregated into a single reporting unit. We test goodwill for impairment at least annually during the fourth fiscal quarter, or more frequently if indicators of

Table of Contents

impairment exist during the fiscal year. Events or circumstances which could trigger an impairment review include a significant decline in market capitalization, adverse change in legal factors or in the business climate, loss of key customers, an adverse action or assessment by a regulator, unanticipated competition, a loss of key personnel, significant changes in the manner of our use of the acquired assets or the strategy for our overall business, significant negative industry or economic trends or significant underperformance relative to expected historical or projected future results of operations. When testing goodwill for impairment, we first perform a qualitative assessment. If we determine it is not more likely than not that a reporting unit’s fair value is less than its carrying amount, then no further analysis is necessary. If we determine it is more likely than not that a reporting unit’s fair value is less than its carrying amount, then we compare the estimated fair value of the reporting unit with its carrying amount, including goodwill. If the estimated fair value of the reporting unit exceeds its carrying amount, goodwill is not considered to be impaired. If, however, the fair value of the reporting unit is less than its carrying amount, the difference between the carrying value and the fair value would be recorded as an impairment loss. Any impairment loss is limited to the carrying amount of goodwill allocated to the reporting unit.

We estimate the fair value of our reporting units using a weighted approach that considers a discounted cash flow method, a market multiple method, and a similar transactions method. Under the discounted cash flow approach, we project future cash flows which are discounted using a weighted-average cost of capital analysis that reflects current market conditions, adjusted for specific reporting unit risks (primarily the uncertainty of achieving projected operating cash flows), in arriving at the fair value of the reporting unit. Under the market multiple approach, we estimate a fair value based on comparable companies’ market multiples of revenues and under the similar transactions method we estimate a fair value using market multiples of revenue for comparable companies, for which information is available about recent market transactions.

Management’s judgment utilized in the goodwill impairment evaluation is critical. The computations require management to make estimates and assumptions and actual results may differ significantly, particularly if there are significant adverse changes in the operating environment. Critical assumptions that are used as part of a quantitative goodwill evaluation include:

•The potential future revenue, EBITDA and cash flows of the reporting unit. The projections use management’s assumptions about economic and market conditions over the projected period as well as our estimates of future performance and reporting unit revenue, gross margin, expenses and other factors. The resulting revenue, EBITDA and cash flow estimates are based on our most recent business operating plans, and various growth rates are assumed for years beyond the current business plan period. These operating plans include plans to grow our sales, plans to globalize the Company’s workforce, plans to reduce operating costs, and plans for enhancements to our technology and platform infrastructure. Variations in the assumptions, estimates and rates could result in significantly different estimates of fair value.

•Selection of an appropriate discount rate. Calculating the present value of future cash flows requires the selection of an appropriate discount rate, which is based on a weighted-average cost of capital analysis. The discount rate is affected by changes in short-term interest rates and long-term yield as well as variances in the typical capital structure of marketplace participants. Given current economic conditions, it is possible that the discount rate will fluctuate in the near term. We engaged third party experts to assist in the determination of the weighted-average cost of capital used to discount the cash flows for the goodwill impairment tests.

New Accounting Pronouncements

See Note 1 to Sharecare’s consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Emerging Growth Company Accounting Election

Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can choose not to take advantage of the extended transition period and comply with the requirements that apply to non-emerging growth companies, and any such election to not take advantage of the extended transition period is irrevocable. We expect to remain an emerging growth company at least through the end of the 2024 fiscal year and expect to continue to take advantage of the benefits of the extended transition period. This may make it difficult or impossible to compare our financial results with the financial results of another public company that is either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition period exemptions for emerging growth companies because of the potential differences in accounting standards used.

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We have in the past and may in the future be exposed to certain market risks, including interest rate, foreign currency exchange, and financial instrument risks, in the ordinary course of our business. Currently, these risks are not material to our financial condition or results of operations, but they may be in the future.

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in company reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer (who serves as our Principal Executive Officer) and Chief Financial Officer (who serves as our Principal Financial Officer), as appropriate, to allow timely decisions regarding required disclosure.

Evaluation of Disclosure Controls and Procedures

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2024. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective as of March 31, 2024, due solely to the material weakness in our internal control over financial reporting described below. Notwithstanding this material weakness described further below, management believes that the financial statements included in this Quarterly Report on Form 10-Q present fairly in all material respects our financial position, results of operations and cash flows for the periods presented.

Previously Reported Material Weakness

As previously reported in Part II, Item 9A, “Controls and Procedures” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, management identified a material weakness in the Company’s internal control over financial reporting as of December 31, 2023 due to the Company not maintaining adequate internal controls with respect to its revenue recognition evaluation resulting from a change in services provided to a customer, due to untimely communication between cross-functional teams. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.

Remediation Measures

Management is implementing remediation steps to address the material weakness described above. Specifically, during the first quarter of 2024, we began implementing specific remediation actions to address the material weakness, which include the following:

•Conducting training and coaching sessions with cross-functional teams to educate appropriate parties on matters of contractual and operational significance that may have an impact on accounting conclusions and financial reporting;

•Establishing and maintaining periodic meetings between cross-functional teams specific to complex customer contracts to evaluate for potential changes in relationships and services provided to customers that could impact accounting decisions.

Limitations on Effectiveness of Controls and Procedures

Our management, including our principal executive officer and principal financial officer, do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Due to inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Changes in Internal Control over Financial Reporting

Except as described above, there have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 of the SEC that occurred during our last quarter ended

Table of Contents

March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

Part II - Other Information

ITEM 1. LEGAL PROCEEDINGS

From time-to-time, we may be subject to various legal proceedings and claims that arise in the normal course of our business activities. Although the results of these legal proceedings, claims, and investigations cannot be predicted with certainty, we do not believe that the final outcome of any matters that we, or any of our subsidiaries, are currently involved in are reasonably likely to have a material adverse effect on our business, financial condition or results of operations. Regardless of final outcomes, however, any such proceedings, claims and investigations may nonetheless impose a significant burden on management and employees and be costly to defend, with unfavorable preliminary or interim rulings.

The section entitled “Legal Matters” in Note 7 to Sharecare’s consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q is incorporated by reference herein.

ITEM 1A. RISK FACTORS

Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in our Annual Report on Form 10-K filed with the SEC on March 29, 2024. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.

As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K filed with the SEC on March 29, 2024. However, we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following table provides information about the purchases of shares of our common stock during the three months ended March 31, 2024:


Period	Total number of shares purchased	Average price paid per share		Total number of shares purchased as part of publicly announced program(1)	Approximate dollar value of shares that may yet be purchased under the program
January 1, 2024 through January 31, 2024	—	$	—	—	$	40,774,500
February 1, 2023 through February 29, 2024	—	$	—	—	$	40,774,500
March 1, 2024 through March 31, 2024	—	$	—	—	$	40,774,500
Totals	—	$	—	—	$	40,774,500

(1) On May 31, 2023, the Board of Directors announced that it had re-authorized a $50 million stock repurchase program. The stock repurchase program has a 12-month term from May 31, 2023 to May 31, 2024. As of March 31, 2024, a dollar value of approximately $40.8 million in shares authorized remain available to be repurchased. There were no other repurchase programs announced as of March 31, 2024.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

During the quarter ended March 31, 2024, none of our directors or executive officers adopted, modified, or terminated any contract, instruction, or written plan for the purchase or sale of our common stock that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”

Table of Contents

ITEM 6. EXHIBITS


Exhibit						Description
3.1						Second Amended and Restated Bylaws of Sharecare, Inc. (incorporated by reference to Exhibit 3.3 to the Company’s Annual Report on Form 10-K, filed with the SEC on March 29, 2024)
10.1#†						Employment Agreement by and among the Company, Sharecare Operating Company, Inc. and Brent Layton, dated February 5, 2024 (incorporated by reference to Exhibit 10 .7 to the Company’s Annual Report on Form 10-K, filed with the SEC on March 29, 2024 )
31.1*						Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*						Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**						Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**						Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*						Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*						Inline XBRL Taxonomy Extension Schema Document
101.CAL*						Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*						Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*						Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*						Inline XBRL Taxonomy Extension Presentation Linkbase Document
104						The cover page for the Company’s Quarterly Report on Form 10-Q has been formatted in Inline XBRL and contained in Exhibit 101

____________


*			Filed herewith
**			Furnished herewith
#			Indicates a management contract or compensatory plan or arrangement
†			Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Dated: May 9, 2024	SHARECARE, INC.

	By: /s/ Brent Layton
	Name:	Brent Layton
	Title:	Chief Executive Officer (Principal Executive Officer)

	By: /s/ Justin Ferrero
	Name:	Justin Ferrero
	Title:	President and Chief Financial Officer (Principal Financial Officer)

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13a-14(a) AS

ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Brent Layton, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Sharecare, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 9, 2024

/s/ Brent Layton

Brent Layton

Chief Executive Officer

(Principal Executive Officer)

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13a-14(a) AS

ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Justin Ferrero, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Sharecare, Inc.;

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 9, 2024

/s/ Justin Ferrero

Justin Ferrero

President and Chief Financial Officer

(Principal Financial Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Sharecare, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2024, as filed with the Securities and Exchange Commission (the “Report”), I, Brent Layton, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

Date: May 9, 2024




By:						/s/ Brent Layton
						Brent Layton
						Chief Executive Officer
						(Principal Executive Officer)

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Sharecare, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2024, as filed with the Securities and Exchange Commission (the “Report”), I, Justin Ferrero, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

Date: May 9, 2024




By:						/s/ Justin Ferrero
						Justin Ferrero
						President and Chief Financial Officer
						(Principal Financial Officer)

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2024	May 06, 2024
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-39535
Entity Registrant Name	SHARECARE, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-1365053
Entity Address, Address Line One	255 East Paces Ferry Road NE,
Entity Address, Address Line Two	Suite 700
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30305
City Area Code	404
Local Phone Number	671-4000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		362,409,958
Entity Central Index Key	0001816233
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false
Common Stock, par value $0.0001 per share
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	SHCR
Security Exchange Name	NASDAQ
Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $11.50 per share
Entity Information [Line Items]
Title of 12(b) Security	Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $11.50 per share
Trading Symbol	SHCRW
Security Exchange Name	NASDAQ

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 100,320	$ 128,187
Accounts receivable, net (net of allowance for doubtful accounts of $8,348 and $8,544, respectively)	124,936	128,173
Other receivables	2,213	2,262
Prepaid expenses	9,875	6,007
Other current assets	2,814	3,178
Total current assets	240,158	267,807
Property and equipment, net	2,751	3,375
Other long-term assets	13,599	13,863
Intangible assets, net	130,263	136,552
Goodwill	191,860	192,037
Total assets	578,631	613,634
Current liabilities:
Accounts payable	45,530	45,388
Accrued expenses and other current liabilities (Note 3)	55,516	65,706
Deferred revenue	5,735	5,517
Total current liabilities	106,781	116,611
Warrant liabilities	317	403
Long-term debt	586	519
Other long-term liabilities	7,171	8,032
Total liabilities	114,855	125,565
Commitments and contingencies (Note 7)
Series A redeemable convertible preferred stock, $0.0001 par value; 5,000,000 shares authorized; 5,000,000 shares issued and outstanding, aggregate liquidation preference of $50,000 as of March 31, 2024 and December 31, 2023	58,205	58,205
Stockholders’ equity:
Common stock $0.0001 par value; 600,000,000 and 600,000,000 shares authorized; 358,572,273 and 353,430,357 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	36	35
Additional paid-in capital	1,168,869	1,157,737
Accumulated other comprehensive loss	(2,551)	(2,263)
Accumulated deficit	(760,460)	(725,373)
Total Sharecare, Inc. stockholders’ equity	405,894	430,136
Noncontrolling interest in subsidiaries	(323)	(272)
Total stockholders’ equity	405,571	429,864
Total liabilities, redeemable convertible preferred stock and stockholders’ equity	$ 578,631	$ 613,634

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Accounts receivable, allowance for doubtful accounts	$ 8,348	$ 8,544
Stockholders’ equity:
Common stock, par value (in USD per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares, issued (in shares)	358,572,273	353,430,357
Common stock, shares, outstanding (in shares)	358,572,273	353,430,357
Series A Preferred Stock
Temporary Equity [Line Items]
Redeemable convertible preferred stock, par value (in USD per share)	$ 0.0001	$ 0.0001
Redeemable convertible preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Redeemable convertible preferred stock, shares issued (in shares)	5,000,000	5,000,000
Redeemable convertible preferred stock, shares outstanding (in shares)	5,000,000	5,000,000
Redeemable convertible preferred stock, aggregate liquidation preference	$ 50,000	$ 50,000

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 90,861	$ 116,295
Costs and operating expenses:
Costs of revenue (exclusive of depreciation and amortization)	51,121	67,890
Sales and marketing	13,558	15,348
Product and technology	14,544	20,808
General and administrative	34,907	34,121
Depreciation and amortization	13,331	14,781
Total costs and operating expenses	127,461	152,948
Loss from operations	(36,600)	(36,653)
Other income:
Interest income	1,274	1,680
Interest expense	(217)	(430)
Other income	368	429
Total other income	1,425	1,679
Loss before income tax benefit (expense)	(35,175)	(34,974)
Income tax benefit (expense)	31	(31)
Net loss	(35,144)	(35,005)
Net loss attributable to noncontrolling interest in subsidiaries	(57)	(346)
Net loss attributable to Sharecare, Inc.	$ (35,087)	$ (34,659)
Net Loss per Share
Net loss per share attributable to common stockholders, basic (in USD per share)	$ (0.10)	$ (0.10)
Net loss per share attributable to common stockholders, diluted (in USD per share)	$ (0.10)	$ (0.10)
Weighted-average common shares outstanding, basic (in shares)	354,208,908	352,923,217
Weighted-average common shares outstanding, diluted (in shares)	354,208,908	352,923,217
Comprehensive loss attributable to Sharecare, Inc.
Net loss	$ (35,144)	$ (35,005)
Foreign currency translation	(282)	307
Comprehensive loss	(35,426)	(34,698)
Comprehensive loss (income) attributable to noncontrolling interest in subsidiaries	(51)	(289)
Comprehensive loss attributable to Sharecare, Inc.	$ (35,375)	$ (34,409)

CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Cumulative effect of adopting ASU 2016-13	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Accumulated Deficit Cumulative effect of adopting ASU 2016-13	Noncontrolling Interest	Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock, beginning balance (in shares) at Dec. 31, 2022									5,000,000
Redeemable convertible preferred stock, beginning balance at Dec. 31, 2022									$ 58,205
Redeemable convertible preferred stock, ending balance (in shares) at Mar. 31, 2023									5,000,000
Redeemable convertible preferred stock, ending balance at Mar. 31, 2023									$ 58,205
Beginning balance (in shares) at Dec. 31, 2022			354,463,620
Beginning balance at Dec. 31, 2022	$ 522,600	$ (1,055)	$ 35	$ 1,120,024	$ (2,794)	$ (595,820)	$ (1,055)	$ 1,155
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)			281,042
Stock options exercised	282			282
Common stock issued upon vesting of restricted stock units (in shares)			1,759,615
Issuance of warrants in connection with debt and revenue arrangements	14			14
Share-based compensation	10,406			10,406
Net income (loss) attributable to noncontrolling interest in subsidiaries	(346)							(346)
Currency translation adjustment	307				250			57
Common stock repurchased related to tax withholding for exercised employee stock options and vested restricted stock units (in shares)			(214,984)
Common stock repurchased related to tax withholding for exercised employee stock options and vested restricted stock units	(396)			(396)
Net income (loss) attributable to Sharecare, Inc.	(34,659)					(34,659)
Other	(131)			(131)
Ending balance (in shares) at Mar. 31, 2023			356,289,293
Ending balance at Mar. 31, 2023	497,022		$ 35	1,130,199	(2,544)	(631,534)		866
Redeemable convertible preferred stock, beginning balance (in shares) at Dec. 31, 2023									5,000,000
Redeemable convertible preferred stock, beginning balance at Dec. 31, 2023	58,205								$ 58,205
Redeemable convertible preferred stock, ending balance (in shares) at Mar. 31, 2024									5,000,000
Redeemable convertible preferred stock, ending balance at Mar. 31, 2024	$ 58,205								$ 58,205
Beginning balance (in shares) at Dec. 31, 2023	353,430,357		353,430,357
Beginning balance at Dec. 31, 2023	$ 429,864		$ 35	1,157,737	(2,263)	(725,373)		(272)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)	40,278		40,278
Stock options exercised	$ 24			24
Common stock issued upon vesting of restricted stock units (in shares)			7,674,863
Common stock issued upon vesting of restricted stock units	0		$ 1	(1)
Issuance of warrants in connection with debt and revenue arrangements	27			27
Share-based compensation	13,866			13,866
Net income (loss) attributable to noncontrolling interest in subsidiaries	(57)							(57)
Currency translation adjustment	(282)				(288)			6
Common stock repurchased related to tax withholding for exercised employee stock options and vested restricted stock units (in shares)			(2,573,225)
Common stock repurchased related to tax withholding for exercised employee stock options and vested restricted stock units	(2,784)			(2,784)
Net income (loss) attributable to Sharecare, Inc.	$ (35,087)					(35,087)
Ending balance (in shares) at Mar. 31, 2024	358,572,273		358,572,273
Ending balance at Mar. 31, 2024	$ 405,571		$ 36	$ 1,168,869	$ (2,551)	$ (760,460)		$ (323)

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (35,144)	$ (35,005)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	13,331	14,781
Non-cash interest expense	68	254
Amortization of contract liabilities	0	(451)
Accretion of contract liabilities	0	68
Lease right-of-use assets expense	566	1,138
Change in fair value of warrant liability and contingent consideration	(379)	(138)
Share-based compensation	13,596	9,969
Deferred income taxes	(36)	59
Other	151	2,120
Changes in operating assets and liabilities:
Accounts receivable, net	2,842	(1,387)
Prepaid expenses and other assets	(3,747)	(5,795)
Accounts payable and accrued expenses	(10,422)	(10,608)
Operating lease liabilities	(635)	794
Deferred revenue	218	703
Net cash used in operating activities	(19,591)	(23,498)
Cash flows from investing activities:
Purchases of property and equipment	(51)	(368)
Capitalized internal-use software costs	(5,135)	(4,806)
Net cash used in investing activities	(5,186)	(5,174)
Cash flows from financing activities:
Payments for shares repurchased	(2,784)	(131)
Proceeds from exercise of common stock options	24	1,023
Payments on financing lease obligations	(285)	(370)
Net cash (used in) provided by financing activities	(3,045)	522
Effect of exchange rates on cash and cash equivalents	(45)	72
Net decrease in cash and cash equivalents	(27,867)	(28,078)
Cash and cash equivalents at beginning of period	128,187	182,508
Cash and cash equivalents at end of period	100,320	154,430
Supplemental disclosure of cash flow information:
Cash paid for interest	151	236
Cash paid for amounts included in the measurement of lease liabilities	626	1,336
Assets obtained in exchange for lease obligations	$ 0	$ 1,695

Nature of Business and Significant Accounting Policies

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Nature of Business and Significant Accounting Policies

Nature of Business

Basis of Presentation and Consolidation Policy

Segment Information

Unaudited Interim Financial Information

Use of Estimates

Concentration of Credit Risk

Fair Value Measurements

•Level 1 — Quoted prices in active markets for identical assets or liabilities

•Level 3 — Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability

Assets and Liabilities that are Measured at Fair Value on a Non-recurring Basis

Accounts Receivable and Allowance for Doubtful Accounts

The changes in the allowance for doubtful accounts are as follows (in thousands):


	Three Months Ended March 31,
	2024		2023
Allowance for doubtful accounts – beginning balance	$	8,544	$	7,197
Provision for doubtful accounts	411		1,869
Amounts written off and other adjustments	(607)		(640)
Allowance for doubtful accounts – ending balance	$	8,348	$	8,426

Contract Liabilities

Deferred Revenue

The Company records contract liabilities, which consist of deferred revenue and contract billings in excess of earned revenue, pursuant to ASC 606.

Revenue Recognition

Performance-Based Revenue

Remaining Performance Obligations

Disaggregated Revenue

The following table presents the Company’s revenues disaggregated by revenue source (in thousands):


	Three Months Ended March 31,
	2024		2023
Enterprise	$	46,960	$	70,193
Provider	28,427		28,974
Life Sciences	15,474		17,128
Total Revenue	$	90,861	$	116,295

Other Income

For the three months ended March 31, 2024 and 2023, other income (expense) consisted of the following (in thousands):


	Three Months Ended March 31,
	2024		2023
Re-measurement of contingent consideration	$	294	$	138
Re-measurement of warrant liabilities	85		—
Other	(11)		291
Total other income	$	368	$	429

Accounting Standards Not Yet Adopted

The ASU is effective for public entities for annual periods beginning after December 15, 2024. We are still evaluating the impact on our financial statement disclosures.

Fair Value Measurements

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Fair Value Measurements

The following tables present the fair value hierarchy for assets and liabilities measured at fair value as of March 31, 2024 (in thousands):


	March 31, 2024
	Level 1		Level 2		Level 3		Total Fair Value
Cash equivalents
Money market funds	$	10,470	$	—	$	—	$	10,470
Total cash equivalents at fair value	$	10,470	$	—	$	—	$	10,470

Liabilities
Warrant liabilities	$	317	$	—	$	—	$	317
Contingent consideration – other liabilities	—		—		101		101
Total liabilities at fair value	$	317	$	—	$	101	$	418

The following is a schedule of changes to the contingent consideration — other liabilities classified as Level 3 for the periods presented (in thousands):


December 31, 2023	$	395
Re-measurement of contingent consideration	(294)
March 31, 2024	$	101

Balance Sheet Components

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Balance Sheet Components

Accrued Expenses and Other Current Liabilities

As of March 31, 2024 and December 31, 2023, accrued expenses and other current liabilities consisted of the following (in thousands):


	March 31, 2024		December 31, 2023
Accrued expenses	$	17,304	$	15,546
Accrued compensation	10,506		16,235
Accrued media costs	2,506		5,168
Accrued taxes	1,509		1,837
Operating lease liabilities, current	1,684		1,826
Contract liability due to the Series A Preferred Stockholder	17,496		17,496
Accrued expenses due to the Series A Preferred Stockholder	3,255		6,084
Accrued other	1,256		1,514
Total accrued expenses and other current liabilities	$	55,516	$	65,706

Goodwill and Other Intangible Assets

3 Months Ended

Mar. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

Intangible assets and the related accumulated amortization for each class of intangible asset as of March 31, 2024 were as follows (in thousands):


	March 31, 2024
	Cost		Accumulated Amortization		Net		Weighted Average Remaining Life
Definite-lived, intangible assets
Technology – features/content	$	62,926	$	(29,650)	$	33,276	7.2
Trade name	3,549		(2,091)		1,458		3.3
Customer relationships	77,849		(41,121)		36,728		8.2
Internal-use software	189,631		(140,630)		49,001		1.8
Total definite-lived, intangible assets	$	333,955	$	(213,492)	$	120,463

Intangible assets not subject to amortization
Internal-use software projects in process	$	4,770	$	—	$	4,770
Indefinite-lived, trade names	5,030		—		5,030
Total intangible assets not subject to amortization	9,800		—		9,800
Total intangible assets	$	343,755	$	(213,492)	$	130,263

The following tables set forth the changes in the carrying amount of the Company’s goodwill for the period presented (in thousands):


December 31, 2023	$	192,037
Foreign currency translation adjustment	(177)
March 31, 2024	$	191,860

The following is a schedule of estimated future amortization expense for intangible assets as of March 31, 2024 (in thousands):


Year ending December 31:
Remainder of 2024	$	33,671
2025	31,239
2026	17,572
2027	10,104
2028	6,932
Thereafter	20,945
Total	$	120,463

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesAs a result of the Company’s history of net operating losses, the Company has provided for a full valuation allowance against its deferred tax assets, with the exception of its German and French operations. For the three months ended March 31, 2024, the Company recognized income tax benefit of less than $0.1 million, primarily due to tax on foreign income. For the three months ended March 31, 2023, the Company recognized income tax benefit of less than $0.1 million, primarily due to tax on foreign income.

Common Stock and Stockholders' Equity

3 Months Ended

Mar. 31, 2024

Equity [Abstract]

Common Stock and Stockholders' Equity

Common Stock and Stockholders’ Equity

Warrants

As of March 31, 2024, the following warrants to purchase common stock were issued and outstanding:


Classification	Warrants Outstanding	Exercise Price per Share
Equity	1,278,746	$4.21 - $5.61
Liability	17,433,334	$11.50

Share-based Payments

Stock option and restricted stock unit activity, prices, and values during the three months ended March 31, 2024 are as follows (in thousands, except share and per share amounts):


	Options Outstanding						Restricted Stock Units
	Number of Options	Weighted- Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in thousands)		Number of Plan shares outstanding	Weighted-Average Grant Date Fair Value per share
Outstanding as of December 31, 2023	92,218,339	$	3.01	5.87	$	1,256	49,007,766	$	1.93
Granted	—	—					15,089,859	$	1.03
Exercised/Released	(40,278)	$	0.59		$	7	(7,674,699)	$	2.38
Cancelled/Forfeited	(2,685,153)	$	2.40				(661,764)	$	1.85
Outstanding as of March 31, 2024	89,492,908	$	3.03	5.58	$	260	55,761,162	$	1.62
Vested and/or exercisable as of March 31, 2024	73,764,072	$	1.88	5.24	$	260
Vested and/or exercisable as of December 31, 2023	73,902,493	$	1.89	5.49	$	1,256


	Three Months Ended March 31,
	2024		2023
Cost of revenues	$	204	$	111
Sales and marketing	1,508		828
Product and technology	1,664		1,068
General and administrative	10,468		7,962
Total share-based compensation expense	$	13,844	$	9,969

ended March 31, 2024 does not reflect the cost associated with these awards. Upon vesting of these RSUs, amounts will be reclassified from liability to equity.

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Matters From time to time, the Company is subject to litigation in the normal course of business. The Company is of the opinion that, based on the information presently available, the resolution of any such legal matters will not have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. The Company has accrued for losses that are both probable and estimable. We are also party to investigations and legal disputes and losses related to certain matters that are reasonably possible, but at this time, we cannot estimate a loss or range of losses.

Related-Party Transactions	3 Months Ended
Related-Party Transactions	Mar. 31, 2024
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party Transactions Sul América Serviços de Saúde S.A. (Sul América), is a customer of and owns a 49% interest in Sharecare Brasil Servicios de Consultoria, Ltda. As of the year ended December 31, 2023, the Company ended the services contract with this related party and ceased operations of Sharecare Brasil Servicios de Consultoria, Ltda. Revenues recognized for the three-month period ended March 31, 2024 and 2023 from Sul América totaled $0.3 million and $1.3 million, respectively. For the three-month period ended March 31, 2024, the revenues recognized represent variable termination fee revenue, which was previously contrained and for which uncertainty about the variable amount to be received was resolved. The Series A Preferred Stock is held by a customer that also had an employee serving on the Sharecare Board. During the three month period ended June 30, 2023, the board member ceased employment with the customer. Subsequent to the board member’s termination of employment with the customer, this customer was no longer considered a related party. Revenues recognized for this customer for the three months ended March 31, 2023 totaled $6.2 million. As of December 31, 2023, $13.0 million in receivables were outstanding from this related party. During the third quarter of 2022, we entered into a revenue contract with the Series A Preferred Stockholder to provide patient advocacy services. We also entered into separate agreements to purchase distinct goods and services. These agreements are now subject to a dispute. Separate from the above disclosed amounts for this related party, revenues recognized related to these distinct services for the three months ended March 31, 2023 totaled $10.6 million. Additionally, revenue for the three months ended March 31, 2023, included $0.4 million of amortization of contract assets. For the three months ended March 31, 2023, cost of sales totaled $10.9 million. Amounts paid under the agreements that were not determined to be distinct were recorded as a reduction of revenues. As of December 31, 2023, there were $34.3 million in receivables and $51.1 million in accounts payable and accrued expenses recorded in connection with these distinct agreements. Additionally, in 2022 the Company acquired certain intellectual property which was determined to be distinct and recorded an intangible asset, which is being amortized over its estimated useful life. The unamortized balance of intangible asset was $3.1 million as of December 31, 2023. As of March 31, 2024, the receivables, accounts payable, and accrued expenses balances recorded in connection with these distinct agreements remained unchanged. The Company has a customer that was a related party for the year ended December 31, 2023 due to an affiliation with a member of the Sharecare Board. This member was nominated during the first quarter of 2023 and has subsequently ceased employment with the customer. This customer is no longer considered a related party as of December 31, 2023. As of December 31, 2023, $1.0 million in receivables were outstanding from this related party and revenues recognized for the three months ended March 31, 2023 totaled $0.7 million.

Net Loss Per Share

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Net Loss Per Share

Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):


	Three Months Ended March 31,
	2024		2023
Numerator
Net loss	$	(35,144)	$	(35,005)
Less: Net loss attributable to noncontrolling interests in subsidiaries	(57)		(346)
Net loss available to common stockholders	$	(35,087)	$	(34,659)

Denominator
Weighted-average common shares outstanding, basic and diluted	354,208,908		352,923,217
Net loss per share attributable to common stockholders, basic and diluted	$	(0.10)	$	(0.10)


	Three Months Ended March 31,
	2024	2023
Stock options and restricted stock units	2,660,077	30,951,366
Redeemable convertible preferred stock	5,000,000	5,000,000

Total	7,660,077	35,951,366

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company considers events or transactions that occur after the balance sheet date, but before the consolidated financial statements are issued, to provide additional evidence relative to certain estimates or identify matters that require additional disclosures. The Company evaluated subsequent events through, May 9, 2024, the date on which the consolidated financial statements were available to be issued, noting no such material events.

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net income (loss) attributable to Sharecare, Inc.	$ (35,087)	$ (34,659)

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Nature of Business and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation and Unaudited Interim Financial Information	Basis of Presentation and Consolidation Policy The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). Unaudited Interim Financial Information The accompanying interim Consolidated Balance Sheet as of March 31, 2024 and the Consolidated Statements of Operations and Comprehensive Loss, Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit), and Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 are unaudited. These unaudited interim consolidated financial statements are presented in accordance with the rules and regulations of the SEC and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with U.S. GAAP. In management’s opinion, the unaudited interim consolidated financial statements have been prepared on the same basis as the annual financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2024 and the Company’s consolidated results of operations and cash flows for the three months ended March 31, 2024 and 2023. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full fiscal year or any other future interim or annual periods. The information contained within the unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s annual financial statements for the year ended December 31, 2023.
Consolidation Policy	The consolidated financial statements include the accounts of Sharecare, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Segment Information	Segment Information The Company operates as a single operating segment. The Company’s chief operating decision maker is its chief executive officer, who reviews financial information presented on a consolidated basis for purposes of making operating decisions, assessing financial performance and allocating resources for the entire company.
Use of Estimates	Use of Estimates The preparation of these unaudited interim consolidated financial statements in conformity with GAAP requires the use of management estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include goodwill, revenue recognition, stock-based compensation, and income taxes. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
Concentration of Credit Risk	Concentration of Credit Risk The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company’s cash deposits are held with well-known financial institutions and may exceed federally insured limits. The Company grants credit to its customers in the normal course of business and generally requires no collateral from its customers.
Fair Value Measurements	Fair Value Measurements The carrying value of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximates fair value due to their short-term nature. The Company measures financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires management to maximize the use of observable inputs and minimize the use of unobservable inputs. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between willing market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement: •Level 1 — Quoted prices in active markets for identical assets or liabilities •Level 2 — Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities •Level 3 — Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability Assets and Liabilities that are Measured at Fair Value on a Non-recurring Basis Assets and liabilities that may be measured at fair value on a non-recurring basis relate primarily to the Company’s tangible fixed assets and other intangible assets. For these assets, the Company does not periodically adjust the carrying value to fair value except in the event of an impairment. When the Company determines that an impairment has occurred, the carrying value of the asset is reduced to its fair value and an impairment charge is recorded within operating loss in the Consolidated Statements of Operations and Comprehensive Loss.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable, net, consists of trade accounts receivable which are due under normal trade terms requiring payment, typically within 45 days from the invoice date. The allowance for doubtful accounts is based on management's estimate for expected credit losses for outstanding trade accounts receivable and is recorded as an offset to accounts receivable. Changes in the allowance for doubtful accounts are classified as general and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss. The Company determines expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, customer payment patterns, and adjusts based on expectations of changes in macro-economic conditions and customer-specific information that may impact the collectability of outstanding receivables. The Company reassesses the adequacy of the allowance for doubtful accounts each reporting period.
Contract Liabilities	Contract Liabilities In connection with certain acquisitions, the Company has recognized current and noncurrent contract liabilities, representing off-market values associated with certain wellness program royalty agreements. Amortization of these contract liabilities was $0 and $0.5 million for three months ended March 31, 2024 and 2023, respectively, all of which was included within cost of revenues in the Consolidated Statements of Operations and Comprehensive Loss. Additionally, the Company has recognized certain contract liabilities due to a former related party in the amount of $17.5 million, related to service agreements, which is included in accrued expenses and other current liabilities in the Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023.
Deferred Revenue and Revenue Recognition	Deferred Revenue The Company records contract liabilities, which consist of deferred revenue and contract billings in excess of earned revenue, pursuant to ASC 606. Deferred revenues arise from contracts that permit upfront billing and the collection of fees covering the entire contractual service period, which is generally six to twelve months and in advance of the satisfaction of the performance obligations identified within the related contract. As of March 31, 2024 and December 31, 2023, such fees were $5.7 million and $5.5 million, respectively. The Company recognized $1.2 million of revenue during the three months ended March 31, 2024 that was included in deferred revenue at December 31, 2023. Revenue Recognition Performance-Based Revenue Certain contracts place a portion of fees at risk based on achieving certain performance metrics, such as customer cost savings, and/or clinical outcomes improvements (performance-based). The Company uses the most likely amount method to estimate variable consideration for these performance guarantees. The Company includes in the transaction price some, or all, of a variable consideration amount only to the extent that it is not probable that a significant reversal in the amount of cumulative revenue recognized will occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company utilizes customer data to measure performance. Performance-based fees subject to refund that the Company has not recognized as revenues are generally due to either: (1) data from the customer is insufficient or incomplete to measure performance; or (2) interim performance measures indicate that it is not probable that the Company will meet the relevant performance target(s). As of March 31, 2024 and December 31, 2023, such fees included within deferred revenue were $4.8 million and $4.9 million, respectively. In the event that performance measures are not met by the end of the measurement period, typically one year, some or all of the performance-based fees are required to be refunded. During the settlement process under a contract, which generally occurs six to eight months after the end of a contract year, performance-based fees are reconciled and settled. Approximately $1.5 million and $1.2 million of revenues recognized during the three months ended March 31, 2024 and 2023, respectively, were performance-based. As of March 31, 2024 and 2023, the cumulative amount of performance-based revenues that had met the criteria for recognition and had been recognized but had not yet been settled with customers, totaled $1.9 million and $6.5 million, respectively. During the three months ended March 31, 2024, $0.7 million of revenue was recognized, which related to services provided prior to December 31, 2023. Remaining Performance Obligations Remaining performance obligations represent contracted revenues that are non-cancellable and have not yet been recognized due to unsatisfied or partially satisfied performance obligations. This includes deferred revenues and amounts that will be invoiced and recognized as revenues in future periods. As of March 31, 2024, future estimated revenue related to performance obligations with terms of more than one year that are unsatisfied or partially unsatisfied at the end of the reporting period was approximately $61.2 million. As of March 31, 2024, the Company expects to recognize revenue on approximately 91% of these unsatisfied performance obligations over the following 24 months and the remainder thereafter.
Accounting Standards Not Yet Adopted	Accounting Standards Not Yet Adopted As an emerging growth company (“EGC”), the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are applicable to private companies (that is, those that have not had a registration statement declared effective under the Securities Act of 1933, as amended (the “Securities Act”), or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company has elected to use this extended transition period under the JOBS Act until such time as the Company is no longer considered to be an EGC. The adoption dates discussed below reflect this election. Income Taxes. In December 2023, the FASB issued ASU No. 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." The new ASU requires public business entities, on an annual basis, to provide a tabular rate reconciliation (using both percentages and reporting currency amounts) of (1) the reported income tax expense (or benefit) from continuing operations, to (2) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal (national) income tax rate of the jurisdiction (country) of domicile using specific categories and separate disclosure for any reconciling items within certain categories that are equal to or greater than a specified quantitative threshold. A public business entity is required to provide an explanation, if not otherwise evident, of the individual reconciling items disclosed, such as the nature, effect, and underlying causes of the reconciling items and the judgment used in categorizing the reconciling items. For each annual period presented, the ASU requires all reporting entities to disclose the year-to-date amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign. It also requires additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The ASU requires that all reporting entities disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign, and income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign. The ASU is effective for public entities for annual periods beginning after December 15, 2024. We are still evaluating the impact on our financial statement disclosures. Segment Reporting. In November 2023, the FASB issued ASU No. 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." The amendments in this update address the requirement for a public entity to disclose its significant segment expense categories and amounts for each reportable segment. A significant segment expense is any significant expense incurred by the segment, including direct expenses, shared expenses, allocated corporate overhead, or interest expense that is regularly reported to the chief operating decision maker and is included in the measure of segment profit or loss. The disclosure of significant segment expenses is in addition to the current specifically-enumerated segment expenses required to be disclosed, such as depreciation and interest expense. If a public entity does not disclose any significant segment expenses for a reportable segment, it is required to disclose narratively the nature of the expenses used by the chief operating decision maker to manage the segment's operations. The ASU is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. We are still evaluating the impact on our financial statement disclosures as it pertains to the Company’s single reportable segment.

Nature of Business and Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Schedule of Allowance for Doubtful Accounts

The changes in the allowance for doubtful accounts are as follows (in thousands):


	Three Months Ended March 31,
	2024		2023
Allowance for doubtful accounts – beginning balance	$	8,544	$	7,197
Provision for doubtful accounts	411		1,869
Amounts written off and other adjustments	(607)		(640)
Allowance for doubtful accounts – ending balance	$	8,348	$	8,426

Schedule of Revenues Disaggregated by Revenue Source

The following table presents the Company’s revenues disaggregated by revenue source (in thousands):


	Three Months Ended March 31,
	2024		2023
Enterprise	$	46,960	$	70,193
Provider	28,427		28,974
Life Sciences	15,474		17,128
Total Revenue	$	90,861	$	116,295

Schedule of Other Income

For the three months ended March 31, 2024 and 2023, other income (expense) consisted of the following (in thousands):


	Three Months Ended March 31,
	2024		2023
Re-measurement of contingent consideration	$	294	$	138
Re-measurement of warrant liabilities	85		—
Other	(11)		291
Total other income	$	368	$	429

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value

The following tables present the fair value hierarchy for assets and liabilities measured at fair value as of March 31, 2024 (in thousands):


	March 31, 2024
	Level 1		Level 2		Level 3		Total Fair Value
Cash equivalents
Money market funds	$	10,470	$	—	$	—	$	10,470
Total cash equivalents at fair value	$	10,470	$	—	$	—	$	10,470

Liabilities
Warrant liabilities	$	317	$	—	$	—	$	317
Contingent consideration – other liabilities	—		—		101		101
Total liabilities at fair value	$	317	$	—	$	101	$	418

Schedule of Changes to the Warrant Liability and Contingent Consideration

The following is a schedule of changes to the contingent consideration — other liabilities classified as Level 3 for the periods presented (in thousands):


December 31, 2023	$	395
Re-measurement of contingent consideration	(294)
March 31, 2024	$	101

Balance Sheet Components (Tables)	3 Months Ended
Balance Sheet Components (Tables)	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Accrued Expense and Other Current Liabilities	As of March 31, 2024 and December 31, 2023, accrued expenses and other current liabilities consisted of the following (in thousands):

Goodwill and Other Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets

Intangible assets and the related accumulated amortization for each class of intangible asset as of March 31, 2024 were as follows (in thousands):


	March 31, 2024
	Cost		Accumulated Amortization		Net		Weighted Average Remaining Life
Definite-lived, intangible assets
Technology – features/content	$	62,926	$	(29,650)	$	33,276	7.2
Trade name	3,549		(2,091)		1,458		3.3
Customer relationships	77,849		(41,121)		36,728		8.2
Internal-use software	189,631		(140,630)		49,001		1.8
Total definite-lived, intangible assets	$	333,955	$	(213,492)	$	120,463

Intangible assets not subject to amortization
Internal-use software projects in process	$	4,770	$	—	$	4,770
Indefinite-lived, trade names	5,030		—		5,030
Total intangible assets not subject to amortization	9,800		—		9,800
Total intangible assets	$	343,755	$	(213,492)	$	130,263

Schedule of Indefinite-Lived Intangible Assets

Intangible assets and the related accumulated amortization for each class of intangible asset as of March 31, 2024 were as follows (in thousands):


	March 31, 2024
	Cost		Accumulated Amortization		Net		Weighted Average Remaining Life
Definite-lived, intangible assets
Technology – features/content	$	62,926	$	(29,650)	$	33,276	7.2
Trade name	3,549		(2,091)		1,458		3.3
Customer relationships	77,849		(41,121)		36,728		8.2
Internal-use software	189,631		(140,630)		49,001		1.8
Total definite-lived, intangible assets	$	333,955	$	(213,492)	$	120,463

Intangible assets not subject to amortization
Internal-use software projects in process	$	4,770	$	—	$	4,770
Indefinite-lived, trade names	5,030		—		5,030
Total intangible assets not subject to amortization	9,800		—		9,800
Total intangible assets	$	343,755	$	(213,492)	$	130,263

Schedule of Carrying Amount of Goodwill

The following tables set forth the changes in the carrying amount of the Company’s goodwill for the period presented (in thousands):


December 31, 2023	$	192,037
Foreign currency translation adjustment	(177)
March 31, 2024	$	191,860

Schedule of Estimated Future Amortization Expense for Intangible Assets

The following is a schedule of estimated future amortization expense for intangible assets as of March 31, 2024 (in thousands):


Year ending December 31:
Remainder of 2024	$	33,671
2025	31,239
2026	17,572
2027	10,104
2028	6,932
Thereafter	20,945
Total	$	120,463

Common Stock and Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2024

Equity [Abstract]

Schedule of Warrants Issued and Outstanding

As of March 31, 2024, the following warrants to purchase common stock were issued and outstanding:


Classification	Warrants Outstanding	Exercise Price per Share
Equity	1,278,746	$4.21 - $5.61
Liability	17,433,334	$11.50

Schedule of Stock Option Activity

Stock option and restricted stock unit activity, prices, and values during the three months ended March 31, 2024 are as follows (in thousands, except share and per share amounts):


	Options Outstanding						Restricted Stock Units
	Number of Options	Weighted- Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in thousands)		Number of Plan shares outstanding	Weighted-Average Grant Date Fair Value per share
Outstanding as of December 31, 2023	92,218,339	$	3.01	5.87	$	1,256	49,007,766	$	1.93
Granted	—	—					15,089,859	$	1.03
Exercised/Released	(40,278)	$	0.59		$	7	(7,674,699)	$	2.38
Cancelled/Forfeited	(2,685,153)	$	2.40				(661,764)	$	1.85
Outstanding as of March 31, 2024	89,492,908	$	3.03	5.58	$	260	55,761,162	$	1.62
Vested and/or exercisable as of March 31, 2024	73,764,072	$	1.88	5.24	$	260
Vested and/or exercisable as of December 31, 2023	73,902,493	$	1.89	5.49	$	1,256

Schedule of Restricted Stock Unit Activity

Stock option and restricted stock unit activity, prices, and values during the three months ended March 31, 2024 are as follows (in thousands, except share and per share amounts):


	Options Outstanding						Restricted Stock Units
	Number of Options	Weighted- Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in thousands)		Number of Plan shares outstanding	Weighted-Average Grant Date Fair Value per share
Outstanding as of December 31, 2023	92,218,339	$	3.01	5.87	$	1,256	49,007,766	$	1.93
Granted	—	—					15,089,859	$	1.03
Exercised/Released	(40,278)	$	0.59		$	7	(7,674,699)	$	2.38
Cancelled/Forfeited	(2,685,153)	$	2.40				(661,764)	$	1.85
Outstanding as of March 31, 2024	89,492,908	$	3.03	5.58	$	260	55,761,162	$	1.62
Vested and/or exercisable as of March 31, 2024	73,764,072	$	1.88	5.24	$	260
Vested and/or exercisable as of December 31, 2023	73,902,493	$	1.89	5.49	$	1,256

Schedule of Share-Based Compensation Expense for Employee and Nonemployee Options


	Three Months Ended March 31,
	2024		2023
Cost of revenues	$	204	$	111
Sales and marketing	1,508		828
Product and technology	1,664		1,068
General and administrative	10,468		7,962
Total share-based compensation expense	$	13,844	$	9,969

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders

Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):


	Three Months Ended March 31,
	2024		2023
Numerator
Net loss	$	(35,144)	$	(35,005)
Less: Net loss attributable to noncontrolling interests in subsidiaries	(57)		(346)
Net loss available to common stockholders	$	(35,087)	$	(34,659)

Denominator
Weighted-average common shares outstanding, basic and diluted	354,208,908		352,923,217
Net loss per share attributable to common stockholders, basic and diluted	$	(0.10)	$	(0.10)

Schedule of Potential Common Shares Equivalents Excluded from Computation of Diluted Net Loss Per Share

The Company excluded the following potential common share equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:


	Three Months Ended March 31,
	2024	2023
Stock options and restricted stock units	2,660,077	30,951,366
Redeemable convertible preferred stock	5,000,000	5,000,000

Total	7,660,077	35,951,366

Nature of Business and Significant Accounting Policies - Schedule of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Allowance for Doubtful Accounts
Allowance for doubtful accounts – beginning balance	$ 8,544	$ 7,197
Provision for doubtful accounts	411	1,869
Amounts written off and other adjustments	(607)	(640)
Allowance for doubtful accounts – ending balance	$ 8,348	$ 8,426

Nature of Business and Significant Accounting Policies - Contract Liabilities and Deferred Revenue (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Amortization of contract liabilities	$ 0	$ 451
Accrued liabilities and other liabilities	55,516		$ 65,706
Deferred revenue	5,735		5,517
Revenue recognized that was previously in deferred revenue	$ 1,200
Minimum
Disaggregation of Revenue [Line Items]
Contractual service period (in months)	6 months
Maximum
Disaggregation of Revenue [Line Items]
Contractual service period (in months)	12 months
Related Party
Disaggregation of Revenue [Line Items]
Accrued liabilities and other liabilities	$ 17,500		$ 17,500

Nature of Business and Significant Accounting Policies - Performance-Based Revenue (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Performance-based fees not recognized as revenue	$ 4.8		$ 4.9
Performance-based revenue recognized	1.5	$ 1.2
Performance-based revenue recognized but not yet settled with customers	1.9	$ 6.5
Revenue recognized related to services provided in prior period	$ 0.7
Enterprise
Disaggregation of Revenue [Line Items]
Measurement period	1 year
Enterprise \| Minimum
Disaggregation of Revenue [Line Items]
Settlement process term	6 months
Enterprise \| Maximum
Disaggregation of Revenue [Line Items]
Settlement process term	8 months

Nature of Business and Significant Accounting Policies - Remaining Performance Obligations (Narrative) (Details) $ in Millions	Mar. 31, 2024 USD ($)
Accounting Policies [Abstract]
Remaining performance obligations	$ 61.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations percentage to be recognized	91.00%
Unsatisfied performance obligations expected recognition period	24 months

Nature of Business and Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Total Revenue	$ 90,861	$ 116,295
Enterprise
Disaggregation of Revenue [Line Items]
Total Revenue	46,960	70,193
Provider
Disaggregation of Revenue [Line Items]
Total Revenue	28,427	28,974
Life Sciences
Disaggregation of Revenue [Line Items]
Total Revenue	$ 15,474	$ 17,128

Nature of Business and Significant Accounting Policies - Schedule of Other Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Accounting Policies [Abstract]
Re-measurement of contingent consideration	$ 294	$ 138
Re-measurement of warrant liabilities	85	0
Other	(11)	291
Total other income	$ 368	$ 429

Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Liabilities
Derivative liability, statement of financial position	Warrant liabilities
Recurring
Cash equivalents
Total cash equivalents at fair value	$ 10,470
Liabilities
Warrant liabilities	317
Contingent consideration – other liabilities	101
Total liabilities at fair value	418
Recurring \| Money market funds
Cash equivalents
Total cash equivalents at fair value	10,470
Recurring \| Level 1
Cash equivalents
Total cash equivalents at fair value	10,470
Liabilities
Warrant liabilities	317
Contingent consideration – other liabilities	0
Total liabilities at fair value	317
Recurring \| Level 1 \| Money market funds
Cash equivalents
Total cash equivalents at fair value	10,470
Recurring \| Level 2
Cash equivalents
Total cash equivalents at fair value	0
Liabilities
Warrant liabilities	0
Contingent consideration – other liabilities	0
Total liabilities at fair value	0
Recurring \| Level 2 \| Money market funds
Cash equivalents
Total cash equivalents at fair value	0
Recurring \| Level 3
Cash equivalents
Total cash equivalents at fair value	0
Liabilities
Warrant liabilities	0
Contingent consideration – other liabilities	101
Total liabilities at fair value	101
Recurring \| Level 3 \| Money market funds
Cash equivalents
Total cash equivalents at fair value	$ 0

Fair Value Measurements - Narrative (Details) - Warrants	Mar. 31, 2024 $ / shares shares
Class of Warrant or Right [Line Items]
Number of securities called by each warrant (in shares) \| shares	1
Exercise price per share (in USD per share) \| $ / shares	$ 11.50

Fair Value Measurements - Schedule of Changes to the Warrant Liability and Contingent Consideration (Details) - Contingent Consideration $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Changes in liability
Beginning balance	$ 395
Re-measurement of contingent consideration	(294)
Ending balance	$ 101

Balance Sheet Components (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accrued Expenses and Other Current Liabilities
Accrued expenses	$ 17,304	$ 15,546
Accrued compensation	10,506	16,235
Accrued media costs	2,506	5,168
Accrued taxes	1,509	1,837
Operating lease liabilities, current	1,684	1,826
Contract liability due to the Series A Preferred Stockholder	17,496	17,496
Accrued expenses due to the Series A Preferred Stockholder	3,255	6,084
Accrued other	1,256	1,514
Total accrued expenses and other current liabilities	$ 55,516	$ 65,706

Goodwill and Other Intangible Assets - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Definite-lived, intangible assets
Cost	$ 333,955
Accumulated Amortization	(213,492)
Net	120,463
Intangible assets not subject to amortization
Intangible assets not subject to amortization	9,800
Total intangible assets
Total intangible assets, cost	343,755
Total intangible assets, accumulated amortization	(213,492)
Total intangible assets, net	130,263	$ 136,552
Internal-use software projects in process
Intangible assets not subject to amortization
Intangible assets not subject to amortization	4,770
Indefinite-lived, trade names
Intangible assets not subject to amortization
Intangible assets not subject to amortization	5,030
Technology – features/content
Definite-lived, intangible assets
Cost	62,926
Accumulated Amortization	(29,650)
Net	$ 33,276
Weighted Average Remaining Life	7 years 2 months 12 days
Total intangible assets
Total intangible assets, accumulated amortization	$ (29,650)
Indefinite-lived, trade names
Definite-lived, intangible assets
Cost	3,549
Accumulated Amortization	(2,091)
Net	$ 1,458
Weighted Average Remaining Life	3 years 3 months 18 days
Total intangible assets
Total intangible assets, accumulated amortization	$ (2,091)
Customer relationships
Definite-lived, intangible assets
Cost	77,849
Accumulated Amortization	(41,121)
Net	$ 36,728
Weighted Average Remaining Life	8 years 2 months 12 days
Total intangible assets
Total intangible assets, accumulated amortization	$ (41,121)
Internal-use software
Definite-lived, intangible assets
Cost	189,631
Accumulated Amortization	(140,630)
Net	$ 49,001
Weighted Average Remaining Life	1 year 9 months 18 days
Total intangible assets
Total intangible assets, accumulated amortization	$ (140,630)

Goodwill and Other Intangible Assets - Schedule of Carrying Amount of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 192,037
Foreign currency translation adjustment	(177)
Ending balance	$ 191,860

Goodwill and Other Intangible Assets - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Percentage of fair value in excess of book value	10.00%
Basis point increase in weighted average cost of capital	10000.00%
Basis point decrease in annual forecasted revenues	10000.00%
Percentage of decline in fair value, in event increase in weighted average capital	3.00%
Percentage of decline in fair value, in event of decrease in annual forecasted revenue	9.00%
Amortization expense for intangible assets	$ 12.7	$ 14.0

Goodwill and Other Intangible Assets - Schedule of Estimated Future Amortization Expense for Intangible Assets (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Estimated future amortization expense:
Remainder of 2024	$ 33,671
2025	31,239
2026	17,572
2027	10,104
2028	6,932
Thereafter	20,945
Net	$ 120,463

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income tax benefit (less than)	$ 31	$ (31)

Common Stock and Stockholders' Equity - Narrative (Details) $ in Millions		3 Months Ended
	May 31, 2023 installment	Mar. 31, 2024 USD ($) shares	Mar. 31, 2023 USD ($)
Class of Stock [Line Items]
Compensation costs related to share-based payment awards reflected within additional paid-in capital related to capitalizable internally developed software activities \| $		$ 0.2	$ 0.4
RSUs
Class of Stock [Line Items]
Share-based compensation arrangement by share-based payment award, voluntarily elected to forgo, cash base salary, percentage	0.25
Share-based compensation arrangement by share-based payment award, voluntarily elected to forgo, cash base salary	12 months
Number of quarterly installments \| installment	4
Unvested liability \| $		$ 0.4
Contractual and Earnout Arrangements
Class of Stock [Line Items]
Common stock reserved for future issuance (in shares)		3,238,675
Warrants reserved for future issuance (in shares)		6,353,577
Warrants earned but not issued (in shares)		52,589
Liability Warrants
Class of Stock [Line Items]
Warrants expiration period (in years)		7 years
Equity Warrants
Class of Stock [Line Items]
Warrants expiration period (in years)		7 years
Warrants vesting period (in years)		3 years

Common Stock and Stockholders' Equity - Schedule of Warrants Issued and Outstanding (Details)	Mar. 31, 2024 $ / shares shares
Equity
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares) \| shares	1,278,746
Equity \| Minimum
Class of Warrant or Right [Line Items]
Exercise price per share (in USD per share)	$ 4.21
Equity \| Maximum
Class of Warrant or Right [Line Items]
Exercise price per share (in USD per share)	$ 5.61
Liability
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares) \| shares	17,433,334
Exercise price per share (in USD per share)	$ 11.50

Common Stock and Stockholders' Equity - Schedule of Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Options Outstanding - Number of Options
Outstanding, beginning (in shares)	92,218,339
Granted (in shares)	0
Exercised/released (in shares)	(40,278)
Cancelled/forfeited (in shares)	(2,685,153)
Outstanding, ending (in shares)	89,492,908	92,218,339
Vested and/or exercisable (in shares)	73,764,072	73,902,493
Options Outstanding - Weighted Average Exercise Price
Outstanding, beginning (in USD per share)	$ 3.01
Granted (in USD per share)	0
Exercised/released (in USD per share)	0.59
Cancelled/forfeited (in USD per share)	2.40
Outstanding, ending (in USD per share)	3.03	$ 3.01
Vested and/or exercisable (in USD per share)	$ 1.88	$ 1.89
Options, Additional Disclosures
Outstanding, weighted average remaining contractual term	5 years 6 months 29 days	5 years 10 months 13 days
Vested and/or exercisable, weighted average remaining contractual term	5 years 2 months 26 days	5 years 5 months 26 days
Outstanding, aggregate intrinsic value	$ 260	$ 1,256
Exercised, aggregate intrinsic value	7
Vested and/or exercisable, aggregate intrinsic value	$ 260	$ 1,256

Common Stock and Stockholders' Equity - Schedule of Restricted Stock Units (Details) - Restricted Stock Units	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Restricted Stock Units - Number of Plan shares outstanding
Outstanding, beginning (in shares) \| shares	49,007,766
Granted (in shares) \| shares	15,089,859
Exercised/released (in shares) \| shares	(7,674,699)
Cancelled/forfeited (in shares) \| shares	(661,764)
Outstanding, ending (in shares) \| shares	55,761,162
Restricted Stock Units - Weighted-Average Grant Date Fair Value per share
Outstanding, beginning (in USD per share) \| $ / shares	$ 1.93
Granted (in USD per share) \| $ / shares	1.03
Exercised/released (in USD per share) \| $ / shares	2.38
Cancelled/forfeited (in USD per share) \| $ / shares	1.85
Outstanding, ending (in USD per share) \| $ / shares	$ 1.62

Common Stock and Stockholders' Equity - Schedule of Share-Based Compensation Expense for Employee and Nonemployee Options (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation expense	$ 13,844	$ 9,969
Cost of revenues
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation expense	204	111
Sales and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation expense	1,508	828
Product and technology
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation expense	1,664	1,068
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation expense	$ 10,468	$ 7,962

Related-Party Transactions (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
Revenue	$ 90,861	$ 116,295
Other receivables	2,213		$ 2,262
Costs of revenue (exclusive of depreciation and amortization)	51,121	67,890
Accrued liabilities and other liabilities	55,516		65,706
Board of Directors Related Customer
Related Party Transaction [Line Items]
Revenue		6,200
Other receivables			13,000
Series A Preferred Stock Holder
Related Party Transaction [Line Items]
Revenue		10,600
Other receivables			34,300
Share-based compensation		400
Costs of revenue (exclusive of depreciation and amortization)		10,900
Accrued liabilities and other liabilities			51,100
Intangible asset recognized			3,100
Director Affiliated Customer
Related Party Transaction [Line Items]
Revenue		700
Other receivables			$ 1,000
Sul América \| Customer
Related Party Transaction [Line Items]
Revenue	$ 300	$ 1,300
Sharecare Brasil Servicios de Consultoria, Ltda \| Sul América
Related Party Transaction [Line Items]
Noncontrolling interest	49.00%

Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Numerator
Net loss	$ (35,144)	$ (35,005)
Less: Net loss attributable to noncontrolling interests in subsidiaries	(57)	(346)
Net loss available to common stockholders, basic	(35,087)	(34,659)
Net loss available to common stockholders, diluted	$ (35,087)	$ (34,659)
Denominator
Weighted-average common shares outstanding, basic (in shares)	354,208,908	352,923,217
Weighted-average common shares outstanding, diluted (in shares)	354,208,908	352,923,217
Net loss per share attributable to common stockholders, basic (in USD per share)	$ (0.10)	$ (0.10)
Net loss per share attributable to common stockholders, diluted (in USD per share)	$ (0.10)	$ (0.10)

Net Loss Per Share - Schedule of Potential Common Shares Equivalents Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares)	7,660,077	35,951,366
Stock options and restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares)	2,660,077	30,951,366
Redeemable convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares)	5,000,000	5,000,000

Net Loss Per Share - Narrative (Details) - shares	3 Months Ended
Net Loss Per Share - Narrative (Details) - shares	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities (in shares)	7,660,077	35,951,366
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities (in shares)	89,100,000	73,700,000
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities (in shares)	53,500,000	32,500,000